

Frederick R Appelbaum

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/3276278/frederick-r-appelbaum-publications-by-year.pdf>

Version: 2024-04-20

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

823
papers

44,515
citations

102
h-index

203
g-index

904
ext. papers

49,923
ext. citations

5.8
avg, IF

6.9
L-index

#	Paper	IF	Citations
823	Effectiveness of allogeneic hematopoietic cell transplantation for older patients with acute myeloid leukemia. <i>Best Practice and Research in Clinical Haematology</i> , 2021 , 34, 101320	4.2	0
822	Enrollment Characteristics and Outcomes of Hispanic and Black AYA ALL Patients Enrolled on a U.S. Intergroup Clinical Trial: A Comparison of the CALGB 10403 (Alliance) Cohort with U.S. Population-Level Data. <i>Blood</i> , 2021 , 138, 337-337	2.2	
821	Proteogenomic Characterization of Highly Enriched Viable Leukemic Blasts in Acute Myeloid Leukemia: A SWOG Report. <i>Blood</i> , 2021 , 138, 522-522	2.2	
820	Tipifarnib as maintenance therapy did not improve disease-free survival in patients with acute myelogenous leukemia at high risk of relapse: Results of the phase III randomized E2902 trial. <i>Leukemia Research</i> , 2021 , 111, 106736	2.7	0
819	Comparison of myeloid blast counts and variant allele frequencies of gene mutations in myelodysplastic syndrome with excess blasts and secondary acute myeloid leukemia. <i>Leukemia and Lymphoma</i> , 2021 , 62, 1226-1233	1.9	7
818	Superior survival with pediatric-style chemotherapy compared to myeloablative allogeneic hematopoietic cell transplantation in older adolescents and young adults with Ph-negative acute lymphoblastic leukemia in first complete remission: analysis from CALGB 10403 and the CIBMTR. <i>Leukemia</i> , 2021 , 35, 2076-2085	10.7	10
817	Hypomethylating agents as maintenance therapy following allogeneic hematopoietic cell transplantation for myeloid malignancies. <i>Best Practice and Research in Clinical Haematology</i> , 2021 , 34, 101241	4.2	2
816	Associations between complete remission and 2- to 3-year survival following 7 + 3 induction for acute myeloid leukemia. <i>Leukemia and Lymphoma</i> , 2021 , 62, 1967-1972	1.9	0
815	Midostaurin reduces relapse in FLT3-mutant acute myeloid leukemia: the Alliance CALGB 10603/RATIFY trial. <i>Leukemia</i> , 2021 , 35, 2539-2551	10.7	15
814	Multi-Site 11-Year Experience of Less-Intensive versus Intensive Therapies in Acute Myeloid Leukemia. <i>Blood</i> , 2021 ,	2.2	6
813	Biologic Assignment Trial of Reduced-Intensity Hematopoietic Cell Transplantation Based on Donor Availability in Patients 50-75 Years of Age With Advanced Myelodysplastic Syndrome. <i>Journal of Clinical Oncology</i> , 2021 , 39, 3328-3339	2.2	14
812	Blood and marrow transplantation during the emerging COVID-19 pandemic: the Seattle approach. <i>Bone Marrow Transplantation</i> , 2021 , 56, 305-313	4.4	0
811	Optimal dosing of cytarabine in induction and post-remission therapy of acute myeloid leukemia. <i>Leukemia</i> , 2021 , 35, 295-298	10.7	1
810	Hematopoietic Cell Transplantation in the Treatment of Newly Diagnosed Adult Acute Myeloid Leukemia: An Evidence-Based Review from the American Society of Transplantation and Cellular Therapy. <i>Transplantation and Cellular Therapy</i> , 2021 , 27, 6-20		12
809	Comparison of CALGB 10403 (Alliance) and COG AALL0232 toxicity results in young adults with acute lymphoblastic leukemia. <i>Blood Advances</i> , 2021 , 5, 504-512	7.8	9
808	Predicting severe toxicities with intensive induction chemotherapy for adult acute myeloid leukemia: analysis of SWOG Cancer Research Network trials S0106 and S1203. <i>Leukemia and Lymphoma</i> , 2021 , 62, 1774-1777	1.9	
807	NCCN Guidelines Insights: Acute Myeloid Leukemia, Version 2.2021. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2021 , 19, 16-27	7.3	46

806	Impact of pretransplant measurable residual disease on the outcome of allogeneic hematopoietic cell transplantation in adult monosomal karyotype AML. <i>Leukemia</i> , 2020 , 34, 1577-1587	10.7	10
805	A phase II trial evaluating the efficacy of high-dose Radioiodinated Tositumomab (Anti-CD20) antibody, etoposide and cyclophosphamide followed by autologous transplantation, for high-risk relapsed or refractory non-hodgkin lymphoma. <i>American Journal of Hematology</i> , 2020 , 95, 775-783	7.1	2
804	A phase 2 study of ATRA, arsenic trioxide, and gemtuzumab ozogamicin in patients with high-risk APL (SWOG 0535). <i>Blood Advances</i> , 2020 , 4, 1683-1689	7.8	20
803	Yttrium-90-labeled anti-CD45 antibody followed by a reduced-intensity hematopoietic cell transplantation for patients with relapsed/refractory leukemia or myelodysplasia. <i>Haematologica</i> , 2020 , 105, 1731-1737	6.6	8
802	Early achievement of measurable residual disease (MRD)-negative complete remission as predictor of outcome after myeloablative allogeneic hematopoietic cell transplantation in acute myeloid leukemia. <i>Bone Marrow Transplantation</i> , 2020 , 55, 669-672	4.4	4
801	Comparative analysis of total body irradiation (TBI)-based and non-TBI-based myeloablative conditioning for acute myeloid leukemia in remission with or without measurable residual disease. <i>Leukemia</i> , 2020 , 34, 1701-1705	10.7	3
800	Midostaurin in patients with acute myeloid leukemia and FLT3-TKD mutations: a subanalysis from the RATIFY trial. <i>Blood Advances</i> , 2020 , 4, 4945-4954	7.8	13
799	Survival, Nonrelapse Mortality, and Relapse-Related Mortality After Allogeneic Hematopoietic Cell Transplantation: Comparing 2003-2007 Versus 2013-2017 Cohorts. <i>Annals of Internal Medicine</i> , 2020 , 172, 229-239	8	48
798	Regimen-intensity per count-recovery and hospitalization index: A new tool to assign regimen intensity for AML. <i>Cancer Medicine</i> , 2020 , 9, 6515-6523	4.8	3
797	Treosulfan-based conditioning is feasible and effective for cord blood recipients: a phase 2 multicenter study. <i>Blood Advances</i> , 2020 , 4, 3302-3310	7.8	6
796	Impact of NPM1/FLT3-ITD genotypes defined by the 2017 European LeukemiaNet in patients with acute myeloid leukemia. <i>Blood</i> , 2020 , 135, 371-380	2.2	53
795	Outpatient intensive induction chemotherapy for acute myeloid leukemia and high-risk myelodysplastic syndrome. <i>Blood Advances</i> , 2020 , 4, 611-616	7.8	10
794	The relationship between clinical trial accrual volume and outcomes in acute myeloid leukemia: A SWOG/ECOG-ACRIN study (S0106 and E1900). <i>Leukemia Research</i> , 2019 , 78, 29-33	2.7	1
793	Allogeneic hematopoietic cell transplantation compared to chemotherapy consolidation in older acute myeloid leukemia (AML) patients 60-75 years in first complete remission (CR1): an alliance (A151509), SWOG, ECOG-ACRIN, and CIBMTR study. <i>Leukemia</i> , 2019 , 33, 2599-2609	10.7	36
792	Maintenance therapy after allogeneic hematopoietic cell transplantation for acute myeloid leukemia. <i>Best Practice and Research in Clinical Haematology</i> , 2019 , 32, 101109	4.2	8
791	Superior Survival with Post-Remission Pediatric-Inspired Chemotherapy Compared to Myeloablative Allogeneic Hematopoietic Cell Transplantation in Adolescents and Young Adults with Ph-Negative Acute Lymphoblastic Leukemia in First Complete Remission: Comparison of CALGB 10403 to Patients Reported to the CIBMTR. <i>Blood</i> , 2019 , 134, 261-261	2.2	5
790	Acute Myeloid Leukemia, Version 3.2019, NCCN Clinical Practice Guidelines in Oncology. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2019 , 17, 721-749	7.3	191
789	Increasing Lengths of First Complete Remission with 7+3 Induction Chemotherapy for Acute Myeloid Leukemia over the Past Four Decades: Analysis of SWOG Trial Data. <i>Blood</i> , 2019 , 134, 291-291	2.2	

788	Development and Performance of Risk Stratification Models for AML Patients Utilizing ELN-2017 Guidelines and Additional Prognostic Factors: A SWOG Report. <i>Blood</i> , 2019 , 134, 2691-2691	2.2	
787	Comparative Analysis of Total Body Irradiation (TBI)-Based and Non-TBI-Based Myeloablative Conditioning for Acute Myeloid Leukemia in Remission with and without Measurable Residual Disease. <i>Blood</i> , 2019 , 134, 321-321	2.2	
786	Myelodysplastic Syndrome with Excess Blasts and Secondary Acute Myeloid Leukemia: Same Disease with Different Blast Count. <i>Blood</i> , 2019 , 134, 2692-2692	2.2	
785	Pre-transplant bone marrow monocytic myeloid-derived suppressor cell frequency is not associated with outcome after allogeneic hematopoietic cell transplantation for acute myeloid leukemia in remission. <i>Bone Marrow Transplantation</i> , 2019 , 54, 1511-1514	4.4	1
784	A pediatric regimen for older adolescents and young adults with acute lymphoblastic leukemia: results of CALGB 10403. <i>Blood</i> , 2019 , 133, 1548-1559	2.2	178
783	Second cycle remission achievement with 7+3 and survival in adults with newly diagnosed acute myeloid leukemia: analysis of recent SWOG trials. <i>Leukemia</i> , 2019 , 33, 554-558	10.7	6
782	Relative survival following response to 7 + 3 versus azacytidine is similar in acute myeloid leukemia and high-risk myelodysplastic syndromes: an analysis of four SWOG studies. <i>Leukemia</i> , 2019 , 33, 371-378	10.7	6
781	Prognostic Performance of the Augmented Hematopoietic Cell Transplantation-Specific Comorbidity/Age Index in Recipients of Allogeneic Hematopoietic Stem Cell Transplantation from Alternative Graft Sources. <i>Biology of Blood and Marrow Transplantation</i> , 2019 , 25, 1045-1052	4.7	11
780	Report of the relapsed/refractory cohort of SWOG S0919: A phase 2 study of idarubicin and cytarabine in combination with pravastatin for acute myelogenous leukemia (AML). <i>Leukemia Research</i> , 2018 , 67, 17-20	2.7	16
779	Blood and Marrow Transplant Clinical Trials Network Report on the Development of Novel Endpoints and Selection of Promising Approaches for Graft-versus-Host Disease Prevention Trials. <i>Biology of Blood and Marrow Transplantation</i> , 2018 , 24, 1274-1280	4.7	32
778	Phase 1/2 trial of GCLAM with dose-escalated mitoxantrone for newly diagnosed AML or other high-grade myeloid neoplasms. <i>Leukemia</i> , 2018 , 32, 2352-2362	10.7	21
777	High Throughput Drug Screening of Leukemia Stem Cells Reveals Resistance to Standard Therapies and Sensitivity to Other Agents in Acute Myeloid Leukemia. <i>Blood</i> , 2018 , 132, 180-180	2.2	1
776	Safety and Efficacy of Yttrium-90-Labeled Anti-CD45 Antibody (90Y-DOTA-BC8) Followed By a Standard Reduced-Intensity Hematopoietic Stem Cell Transplant (HCT) Regimen for Patients with Refractory/Relapsed Leukemia or High-Risk Myelodysplastic Syndrome (MDS). <i>Blood</i> , 2018 , 132, 1018-1018	2.2	6
775	Survival Differences Among Patients (pts) with Acute Myeloid Leukemia (AML) Treated with Allogeneic Hematopoietic Cell Transplantation (HCT) Versus Non-HCT Therapies: A Large Real-Time Multi-Center Prospective Longitudinal Observational Study. <i>Blood</i> , 2018 , 132, 207-207	2.2	1
774	Comprehensive Molecular Profiling of FLT3-Mutated Acute Myeloid Leukemia (AML) Patients Treated within the Ratify Trial (Alliance C10603). <i>Blood</i> , 2018 , 132, 1534-1534	2.2	1
773	Prognostic Impact of Insertion Site in Acute Myeloid Leukemia (AML) with FLT3 Internal Tandem Duplication: Results from the Ratify Study (Alliance 10603). <i>Blood</i> , 2018 , 132, 435-435	2.2	3
772	Use of Gemtuzumab Ozogamicin for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia (AML) or Acute Promyelocytic Leukemia (APL) in an Expanded Access Setting at Our Cancer Consortium. <i>Blood</i> , 2018 , 132, 2710-2710	2.2	1
771	Predicting Induction Toxicity with 7+3: Analysis of SWOG Trial S1203. <i>Blood</i> , 2018 , 132, 1403-1403	2.2	2

770	Fully Human Bcma Targeted Chimeric Antigen Receptor T Cells Administered in a Defined Composition Demonstrate Potency at Low Doses in Advanced Stage High Risk Multiple Myeloma. <i>Blood</i> , 2018 , 132, 1011-1011	2.2	62
769	Limitations to Receiving Allogeneic Hematopoietic Cell Transplantation for Treatment of Acute Myeloid Leukemia: A Large Multi-Center Prospective Longitudinal Observational Study. <i>Blood</i> , 2018 , 132, 1388-1388	2.2	
768	Predictors of 90-Day Mortality after Admission to Intensive Care Unit (ICU) in Patients with Acute Myeloid Leukemia (AML): Application of a Novel, Recently Validated AML-Specific Risk Model. <i>Blood</i> , 2018 , 132, 3986-3986	2.2	
767	Pre-Transplant Monocytic Myeloid-Derived Suppressor Cell Frequency Has No Prognostic Role for Outcome after Allogeneic Hematopoietic Cell Transplantation for Acute Myeloid Leukemia in Remission. <i>Blood</i> , 2018 , 132, 5255-5255	2.2	
766	2nd cycle Remission Achievement with 7+3 Is Associated with Shorter Survival in Adults with Newly Diagnosed Acute Myeloid Leukemia: Analysis of Recent SWOG Trials. <i>Blood</i> , 2018 , 132, 3978-3978	2.2	
765	Impact of Specimen Heterogeneity on Biomarkers in Repository Samples from Patients with Acute Myeloid Leukemia: A SWOG Report. <i>Biopreservation and Biobanking</i> , 2018 , 16, 42-52	2.1	5
764	Hematopoietic cell transplantation as treatment of patients with acute myeloid leukemia with measurable residual disease after consolidation therapy. <i>Best Practice and Research in Clinical Haematology</i> , 2018 , 31, 405-409	4.2	4
763	Lenalidomide consolidation benefits patients with CLL receiving chemoimmunotherapy: results for CALGB 10404 (Alliance). <i>Blood Advances</i> , 2018 , 2, 1705-1718	7.8	9
762	Next-generation sequencing for measuring minimal residual disease in AML. <i>Nature Reviews Clinical Oncology</i> , 2018 , 15, 473-474	19.4	4
761	Next-Generation Sequencing in Adult B Cell Acute Lymphoblastic Leukemia Patients. <i>Biology of Blood and Marrow Transplantation</i> , 2017 , 23, 691-696	4.7	30
760	Prognostic methylation markers for overall survival in cytogenetically normal patients with acute myeloid leukemia treated on SWOG trials. <i>Cancer</i> , 2017 , 123, 2472-2481	6.4	8
759	Determinants of fatal bleeding during induction therapy for acute promyelocytic leukemia in the ATRA era. <i>Blood</i> , 2017 , 129, 1763-1767	2.2	55
758	Early mortality and overall survival of acute myeloid leukemia based on facility type. <i>American Journal of Hematology</i> , 2017 , 92, 764-771	7.1	34
757	Midostaurin plus Chemotherapy for Acute Myeloid Leukemia with a FLT3 Mutation. <i>New England Journal of Medicine</i> , 2017 , 377, 454-464	59.2	1067
756	Flow cytometric demonstration of decrease in bone marrow leukemic blasts after 'Day 14' without further therapy in acute myeloid leukemia. <i>Leukemia and Lymphoma</i> , 2017 , 58, 2717-2719	1.9	7
755	Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel. <i>Blood</i> , 2017 , 129, 424-447	2.2	2764
754	Impact of allogeneic hematopoietic cell transplantation on the outcome of older patients with acute myeloid leukemia. <i>Best Practice and Research in Clinical Haematology</i> , 2017 , 30, 320-326	4.2	13
753	Gemtuzumab ozogamicin for acute myeloid leukemia. <i>Blood</i> , 2017 , 130, 2373-2376	2.2	96

752	Randomized Phase II Study of Azacitidine Alone or in Combination With Lenalidomide or With Vorinostat in Higher-Risk Myelodysplastic Syndromes and Chronic Myelomonocytic Leukemia: North American Intergroup Study SWOG S1117. <i>Journal of Clinical Oncology</i> , 2017 , 35, 2745-2753	2.2	154
751	Measure for Measure: Measuring the Impact of Measuring Residual Disease in Acute Myeloid Leukemia. <i>Journal of Oncology Practice</i> , 2017 , 13, 481-483	3.1	
750	Development and Validation of a Novel Acute Myeloid Leukemia-Composite Model to Estimate Risks of Mortality. <i>JAMA Oncology</i> , 2017 , 3, 1675-1682	13.4	78
749	Acute Myeloid Leukemia, Version 3.2017, NCCN Clinical Practice Guidelines in Oncology. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2017 , 15, 926-957	7.3	256
748	Comparison of Chronic Graft-Versus-Host Disease Severity and Functional Status after Cord Blood, Haploidentical Related and 1-Allele Mismatched Unrelated Donor Hematopoietic Cell Transplantation. <i>Blood</i> , 2017 , 130, 73-73	2.2	
747	US Intergroup Study of Chemotherapy Plus Dasatinib and Allogeneic Stem Cell Transplant in Philadelphia Chromosome Positive ALL. <i>Blood Advances</i> , 2016 , 1, 250-259	7.8	91
746	Respiratory Viruses After Hematopoietic Cell Transplantation 2016 , 1112-1125		
745	Telomere Length Recovery: A Strong Predictor of Overall Survival in Acute Promyelocytic Leukemia. <i>Acta Haematologica</i> , 2016 , 136, 210-218	2.7	13
744	Hematopoietic Stem Cell Transplantation for Chronic Myeloid Leukemia 2016 , 545-556		
743	Immune Reconstitution Following Hematopoietic Cell Transplantation 2016 , 160-169		3
742	Association between early promoter-specific DNA methylation changes and outcome in older acute myeloid leukemia patients. <i>Leukemia Research</i> , 2016 , 42, 68-74	2.7	9
741	Allogeneic Hematopoietic Cell Transplantation for Acute Myeloid Leukemia: Time to Move Toward a Minimal Residual Disease-Based Definition of Complete Remission?. <i>Journal of Clinical Oncology</i> , 2016 , 34, 329-36	2.2	270
740	Feasibility of Allogeneic Hematopoietic Cell Transplantation Among High-Risk AML Patients in First Complete Remission: Results of the Transplant Objective from the SWOG (S1203) Randomized Phase III Study of Induction Therapy Using Standard 7+3 Therapy or Idarubicin with High-Dose Cytarabine (IA) Versus IA Plus Vorinostat. <i>Blood</i> , 2016 , 128, 1166-1166	2.2	4
739	Complete Remissions (CRs) with Azacitidine Regimens Compared to Crs with 7+3 Induction Chemotherapy and the Effect on Overall Survival. <i>Blood</i> , 2016 , 128, 1613-1613	2.2	2
738	Intensive Versus Non-Intensive Induction Therapy for Patients (Pts) with Newly Diagnosed Acute Myeloid Leukemia (AML) Using Two Different Novel Prognostic Models. <i>Blood</i> , 2016 , 128, 216-216	2.2	16
737	Genomic Subtypes of Nucleophosmin (NPM1) Mutations Are Associated with Clinical Outcome in AML - a COG and SWOG Intergroup Collaboration. <i>Blood</i> , 2016 , 128, 285-285	2.2	2
736	ATRA, Arsenic Trioxide (ATO), and Gemtuzumab Ozogamicin (GO) Is Safe and Highly Effective in Patients with Previously Untreated High-Risk Acute Promyelocytic Leukemia (APL): Final Results of the SWOG/Alliance/ECOG S0535 Trial. <i>Blood</i> , 2016 , 128, 896-896	2.2	7
735	SWOG S1203: A Randomized Phase III Study of Standard Cytarabine Plus Daunorubicin (7+3) Therapy Versus Idarubicin with High Dose Cytarabine (IA) with or without Vorinostat (IA+V) in Younger Patients with Previously Untreated Acute Myeloid Leukemia (AML). <i>Blood</i> , 2016 , 128, 901-901	2.2	33

734	A Precision Medicine Approach Incorporating Both Molecular and In Vitro Functional Data to Treat Patients with Relapsed/Refractory Acute Myeloid Leukemia. <i>Blood</i> , 2016 , 128, 4043-4043	2.2	
733	Improved Prognostic Significance of Genomic and Transcriptional Biomarkers By Examining Enriched Populations of AML Blasts: A SWOG Report. <i>Blood</i> , 2016 , 128, 2890-2890	2.2	
732	Cryopreservation of Hematopoietic Cells 2016 , 469-481		
731	Consolidation chemotherapy prior to hematopoietic cell transplantation for adults with acute myeloid leukemia in first remission. <i>Best Practice and Research in Clinical Haematology</i> , 2016 , 29, 365-374 ²	4	
730	Relationship between event-free survival and overall survival in acute myeloid leukemia: a report from SWOG, HOVON/SAKK, and MRC/NCRI. <i>Haematologica</i> , 2016 , 101, e284-6	6.6	15
729	Association of Distance from Transplantation Center and Place of Residence on Outcomes after Allogeneic Hematopoietic Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2016 , 22, 1319-1323	4.7	22
728	Posttransplantation cyclophosphamide for prevention of graft-versus-host disease after HLA-matched mobilized blood cell transplantation. <i>Blood</i> , 2016 , 127, 1502-8	2.2	119
727	Maintenance therapy in acute myeloid leukemia: an evidence-based review of randomized trials. <i>Blood</i> , 2016 , 128, 763-73	2.2	37
726	Cord-Blood Transplantation in Patients with Minimal Residual Disease. <i>New England Journal of Medicine</i> , 2016 , 375, 944-53	59.2	247
725	Infusion of a non-HLA-matched ex-vivo expanded cord blood progenitor cell product after intensive acute myeloid leukaemia chemotherapy: a phase 1 trial. <i>Lancet Haematology</i> , 2016 , 3, e330-9	14.6	21
724	A History of Allogeneic and Autologous Hematopoietic Cell Transplantation 2016 , 1-11		
723	Histocompatibility 2016 , 112-127		1
722	Biology of the Human Graft-versus-Tumor Response and How to Exploit It 2016 , 166-181		1
721	Uses and Growth of Hematopoietic Cell Transplantation 2016 , 8-17		3
720	Generation of Definitive Engraftable Hematopoietic Stem Cells from Human Pluripotent Stem Cells 2016 , 16-26		1
719	Hematopoietic Stem Cells, Regenerative Medicine, and Leukemogenesis 2016 , 25-57		2
718	Marrow Microenvironment and Biology of Mobilization of Stem Cells 2016 , 50-67		
717	Expansion of Human Hematopoietic Stem Cells 2016 , 62-70		

- 716 Hematopoietic Cell Therapy for Human Immunodeficiency Virus Infection **2016**, 781-793 1
- 715 Mesenchymal Stromal Cells and Hematopoietic Cell Transplantation **2016**, 69-79
- 714 Hematopoietic Cell Transplantation for Immunodeficiency Diseases **2016**, 866-889
- 713 Genetic Manipulation of Hematopoietic Stem Cells **2016**, 78-99
- 712 Overview of Hematopoietic Cell Transplantation Immunology **2016**, 96-114
- 711 Oral Complications of Hematopoietic Cell Transplantation **2016**, 1242-1258 1
- 710 Growth and Development After Hematopoietic Cell Transplantation **2016**, 1257-1268
- 709 Delayed Non-malignant Complications After Hematopoietic Cell Transplantation **2016**, 1266-1276
- 708 Subsequent Malignant Neoplasms After Hematopoietic Cell Transplantation **2016**, 1275-1289 1
- 707 Neurologic Complications of Hematopoietic Cell Transplantation **2016**, 1287-1298 1
- 706 Vaccination of Allogeneic and Autologous Hematopoietic Cell Recipients **2016**, 1297-1306
- 705 Natural Killer Cells and Allogeneic Hematopoietic Cell Transplantation **2016**, 126-138
- 704 Mechanisms of Tolerance **2016**, 136-149 1
- 703 The Pathophysiology of Graft-versus-Host Disease **2016**, 146-155 4
- 702 Immune Regulation in Hematopoietic Cell Transplantation **2016**, 153-162
- 701 Dendritic Cells in Hematopoietic Cell Transplantation **2016**, 178-194
- 700 The Experimental Basis for Hematopoietic Cell Transplantation for Autoimmune Diseases **2016**, 191-214 1
- 699 Pharmacologic Basis for High-dose Chemotherapy **2016**, 211-224 0

698	High-dose Preparatory Regimens 2016 , 223-234	0
697	Reduced-intensity Allogeneic Transplantation Regimens 2016 , 232-246	
696	Radiotherapeutic Principles of Hematopoietic Cell Transplantation 2016 , 244-261	
695	Radioimmunotherapy and Hematopoietic Cell Transplantation 2016 , 258-275	
694	Documentation of Engraftment and Characterization of Chimerism After Hematopoietic Cell Transplantation 2016 , 272-282	1
693	The Detection and Significance of Minimal Residual Disease 2016 , 281-296	
692	Pathology of Hematopoietic Cell Transplantation 2016 , 292-332	3
691	Biostatistical Methods in Hematopoietic Cell Transplantation 2016 , 329-341	
690	Outcomes Research in Hematopoietic Cell Transplantation 2016 , 341-350	
689	The Evaluation and Counseling of Candidates for Hematopoietic Cell Transplantation 2016 , 349-365	
688	Nursing Role in Hematopoietic Cell Transplantation 2016 , 362-374	1
687	Ethical Issues in Hematopoietic Cell Transplantation 2016 , 374-385	
686	Psychosocial Issues in Hematopoietic Cell Transplantation 2016 , 384-393	
685	Assessment of Quality of Life in Hematopoietic Cell Transplantation Recipients 2016 , 392-401	1
684	Sexuality Following Hematopoietic Cell Transplantation 2016 , 399-408	
683	Hematopoietic Cell Transplantation 2016 , 407-414	
682	Hematopoietic Cell Procurement, Processing, and Transplantation 2016 , 414-424	1
681	Bone Marrow and Peripheral Blood Cell Donors and Donor Registries 2016 , 423-432	1

680 The Role of the Transplant Program in a Nuclear Accident or Terrorism **2016**, 431-437

679 Cord Blood Hematopoietic Cell Transplantation **2016**, 437-455

5

678 Mobilization of Peripheral Blood Hematopoietic Cells for Autologous HCT **2016**, 452-462

1

677 Peripheral Blood Hematopoietic Cells for Allogeneic Transplantation **2016**, 460-471

1

676 Use of Recombinant Growth Factors after Hematopoietic Cell Transplantation **2016**, 480-491

675 Hematopoietic Cell Transplantation from Human Leukocyte Antigen Partially Matched Related Donors **2016**, 489-508

674 Hematopoietic Cell Transplantation from Unrelated Donors **2016**, 505-520

673 Hematopoietic Cell Transplantation for Aplastic Anemia **2016**, 517-540

1

672 Hematopoietic Cell Transplantation for Paroxysmal Nocturnal Hemoglobinuria **2016**, 537-546

671 Hematopoietic Cell Transplantation for Juvenile Myelomonocytic Leukemia **2016**, 554-565

670 Hematopoietic Cell Transplantation for Childhood Acute Myeloid Leukemia **2016**, 576-590

669 Hematopoietic Cell Transplantation for Acute Lymphoblastic Leukemia in Adults **2016**, 588-601

668 Hematopoietic Cell Transplantation for Acute Lymphoblastic Leukemia in Children **2016**, 600-617

667 Hematopoietic Cell Transplantation for Myelodysplastic Syndromes and Myeloproliferative Neoplasms **2016**, 613-627

666 Hematopoietic Cell Transplantation for Multiple Myeloma **2016**, 625-639

665 Hematopoietic Cell Transplantation for Hodgkin Disease **2016**, 675-695

664 Hematopoietic Cell Transplantation for Non-Hodgkin Lymphoma (B Cell) **2016**, 692-705

663 Hematopoietic Cell Transplantation for Non-Hodgkin Lymphoma (T Cell) **2016**, 703-716

- 662 Hematopoietic Cell Transplantation for Chronic Lymphocytic Leukemia **2016**, 714-726
- 661 Autologous Hematopoietic Cell Transplantation for Systemic Light Chain (AL-) Amyloidosis **2016**, 724-741 1
- 660 Autologous Hematopoietic Cell Transplantation for Breast Cancer and Germ-cell Tumors **2016**, 739-750
- 659 Hematopoietic Cell Transplantation for Renal Cell Carcinoma and Other Solid Tumors **2016**, 748-761
- 658 Hematopoietic Cell Transplantation for Neuroblastoma **2016**, 760-770
- 657 Hematopoietic Cell Transplantation for Other Pediatric Solid Tumors **2016**, 768-784
- 656 Hematopoietic Cell Transplantation for Autoimmune Diseases **2016**, 792-806
- 655 Hematopoietic Cell Transplantation for Rare Hematologic Malignancies **2016**, 804-819 1
- 654 Adoptive T-cell Therapy for Viral Disease in the Setting of Hematopoietic Cell Transplantation **2016**, 816-827
- 653 Adoptive T-cell Therapy for Malignancy in the Setting of Hematopoietic Cell Transplantation **2016**, 826-838 1
- 652 Relapse of Hematologic Malignancy After Allogeneic Hematopoietic Transplantation **2016**, 836-844
- 651 Hematopoietic Cell Transplantation for Thalassemia **2016**, 842-854 1
- 650 Hematopoietic Cell Transplantation for Sickle Cell Disease **2016**, 853-868
- 649 Hematopoietic Cell Transplantation for Storage Diseases **2016**, 885-912
- 648 Hematopoietic Cell Transplantation for Macrophage, Granulocyte and Osteoclast Disorders **2016**, 910-925
- 647 Hematopoietic Cell Transplantation for Fanconi Anemia **2016**, 923-946 1
- 646 Blood Group Incompatibilities and Hemolytic Complications of Hematopoietic Cell Transplantation **2016**, 955-962 1
- 645 Principles of Transfusion Support Before and After Hematopoietic Cell Transplantation **2016**, 961-979 1

644 Vascular Access and Complications **2016**, 976-991

643 Pharmacologic Prevention of Acute Graft-versus-Host Disease **2016**, 990-1006

3

642 T-cell Depletion to Prevent Graft-versus-Host Disease **2016**, 1004-1014

641 Manifestations and Treatment of Acute Graft-versus-Host Disease **2016**, 1012-1025

5

640 Chronic Graft-versus-Host Disease [Clinical Manifestations and Therapy] **2016**, 1020-1039

1

639 Fungal Infections After Hematopoietic Cell Transplantation **2016**, 1057-1071

1

638 Cytomegalovirus Infection **2016**, 1069-1079

2

637 Herpes Simplex Virus Infections **2016**, 1078-1086

636 Varicella Zoster Virus Infections **2016**, 1085-1110

1

635 EpsteinBarr Virus Infection **2016**, 1105-1113

634 HHV-6A, HHV-6B, HHV-7, and HHV-8 After Hematopoietic Cell Transplantation **2016**, 1122-1131

633 Human Adenovirus, Polyomavirus, and Parvovirus Infections in Patients Undergoing Hematopoietic Stem Cell Transplantation **2016**, 1129-1143

3

632 Gastrointestinal and Hepatic Complications **2016**, 1140-1160

4

631 Lung Injury Following Hematopoietic Cell Transplantation **2016**, 1156-1172

1

630 Kidney and Bladder Complications of Hematopoietic Cell Transplantation **2016**, 1170-1184

629 Endocrine Complications Following Hematopoietic Cell Transplantation **2016**, 1181-1207

1

628 Common Potential Drug Interactions Following Hematopoietic Cell Transplantation **2016**, 1206-1217

1

627 Nutrition Support of the Hematopoietic Cell Transplant Recipient **2016**, 1216-1226

1

626	Practice Patterns and Preferences Among Hematopoietic Cell Transplantation Clinicians. <i>Biology of Blood and Marrow Transplantation</i> , 2016 , 22, 2092-2099	4.7	3
625	Mechanisms and Treatment of Graft Failure 2016 , 944-958		6
624	Reevaluation of the pretransplant assessment of mortality score after allogeneic hematopoietic transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2015 , 21, 848-54	4.7	28
623	Adult Low-Hypodiploid Acute B-Lymphoblastic Leukemia With IKZF3 Deletion and TP53 Mutation: Comparison With Pediatric Patients. <i>American Journal of Clinical Pathology</i> , 2015 , 144, 263-70	1.9	8
622	Prognostic significance of NPM1 mutations in the absence of FLT3-internal tandem duplication in older patients with acute myeloid leukemia: a SWOG and UK National Cancer Research Institute/Medical Research Council report. <i>Journal of Clinical Oncology</i> , 2015 , 33, 1157-64	2.2	86
621	Relation of clinical response and minimal residual disease and their prognostic impact on outcome in acute myeloid leukemia. <i>Journal of Clinical Oncology</i> , 2015 , 33, 1258-64	2.2	163
620	Effect of allogeneic hematopoietic cell transplantation in first complete remission on post-relapse complete remission rate and survival in acute myeloid leukemia. <i>Haematologica</i> , 2015 , 100, e254-6	6.6	3
619	Cytogenetic heterogeneity negatively impacts outcomes in patients with acute myeloid leukemia. <i>Haematologica</i> , 2015 , 100, 331-5	6.6	19
618	Hematopoietic cell transplantation for adults with acute myeloid leukemia with minimal residual disease. <i>Best Practice and Research in Clinical Haematology</i> , 2015 , 28, 133-40	4.2	3
617	Prognostic significance of acquired copy-neutral loss of heterozygosity in acute myeloid leukemia. <i>Cancer</i> , 2015 , 121, 2900-8	6.4	20
616	Hematopoietic Cell Transplantation after Solid Organ Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2015 , 21, 2123-2128	4.7	13
615	Recommendations for donor human leukocyte antigen assessment and matching for allogeneic stem cell transplantation: consensus opinion of the Blood and Marrow Transplant Clinical Trials Network (BMT CTN). <i>Biology of Blood and Marrow Transplantation</i> , 2015 , 21, 4-7	4.7	66
614	Fate of patients with newly diagnosed acute myeloid leukemia who fail primary induction therapy. <i>Biology of Blood and Marrow Transplantation</i> , 2015 , 21, 559-64	4.7	42
613	Empiric definition of eligibility criteria for clinical trials in relapsed/refractory acute myeloid leukemia: analysis of 1,892 patients from HOVON/SAKK and SWOG. <i>Haematologica</i> , 2015 , 100, e409-11	6.6	9
612	Identification of differentially methylated markers among cytogenetic risk groups of acute myeloid leukemia. <i>Epigenetics</i> , 2015 , 10, 526-35	5.7	15
611	Cytogenetic prioritization with inclusion of molecular markers predicts outcome in previously untreated patients with chronic lymphocytic leukemia treated with fludarabine or fludarabine plus cyclophosphamide: a long-term follow-up study of the US intergroup phase III trial E2997. <i>Leukemia</i> , 2015 , 29, 1003-11	1.9	7
610	G-CSF priming, clofarabine, and high dose cytarabine (GCLAC) for upfront treatment of acute myeloid leukemia, advanced myelodysplastic syndrome or advanced myeloproliferative neoplasm. <i>American Journal of Hematology</i> , 2015 , 90, 295-300	7.1	15
609	Reprint of: Allogeneic hematopoietic cell transplantation for acute myeloid leukemia. <i>Biology of Blood and Marrow Transplantation</i> , 2015 , 21, S3-10	4.7	4

608	Number of courses of induction therapy independently predicts outcome after allogeneic transplantation for acute myeloid leukemia in first morphological remission. <i>Biology of Blood and Marrow Transplantation</i> , 2015 , 21, 373-8	4.7	17
607	Tipifarnib As Maintenance Therapy in Acute Myeloid Leukemia (AML) Improves Survival in a Subgroup of Patients with High Risk Disease. Results of the Phase III Intergroup Trial E2902. <i>Blood</i> , 2015 , 126, 1308-1308	2.2	5
606	Effect of Minimal Residual Disease (MRD) Information on Prediction of Relapse and Survival in Adult Acute Myeloid Leukemia. <i>Blood</i> , 2015 , 126, 2569-2569	2.2	1
605	The Multi-Kinase Inhibitor Midostaurin (M) Prolongs Survival Compared with Placebo (P) in Combination with Daunorubicin (D)/Cytarabine (C) Induction (ind), High-Dose C Consolidation (consol), and As Maintenance (maint) Therapy in Newly Diagnosed Acute Myeloid Leukemia (AML) Patients (n=1012) with FLT3 Internal Transcription Site (ITD) Mutations: A Randomized	2.2	93
604	Multi-Center US Intergroup Study of Intensive Chemotherapy Plus Dasatinib Followed By Allogeneic Stem Cell Transplant in Patients with Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia Younger Than 60. <i>Blood</i> , 2015 , 126, 796-796	2.2	8
603	Additional Analyses of a Randomized Phase II Study of Azacitidine Combined with Lenalidomide or with Vorinostat Vs. Azacitidine Monotherapy in Higher-Risk Myelodysplastic Syndromes (MDS) and Chronic Myelomonocytic Leukemia (CMML): North American Intergroup Study SWOG S1117. <i>Blood</i> , 2015 , 126, 888-888	2.2	14
602	Cell signaling-based classifier predicts response to induction therapy in elderly patients with acute myeloid leukemia. <i>PLoS ONE</i> , 2015 , 10, e0118485	3.7	4
601	Report of the Relapsed/Refractory Cohort of SWOG S0919: A Phase 2 Study of Idarubicin and Cytarabine in Combination with Pravastatin for Acute Myelogenous Leukemia. <i>Blood</i> , 2015 , 126, 3803-3803	2.2	2
600	A Phase II Trial of Radioimmunotherapy-Based Autologous Transplantation with I-131 Tositumomab, Cyclophosphamide and Etoposide in Relapsed/Refractory Diffuse Large B-Cell Lymphoma. <i>Blood</i> , 2015 , 126, 5502-5502	2.2	
599	Allogeneic Hematopoietic Cell Transplantation for Acute Myeloid Leukemia: Is It Time to Move Toward a Minimal Residual Disease-Based Definition of Complete Remission?. <i>Blood</i> , 2015 , 126, 2571-2571	2.2	2
598	Defining the Genomic Make up of Acute Myeloid Leukemia in Adolescents and Young Adults (AYA): Report from COG AAML03P1, AAML531 and SWOG S0106. <i>Blood</i> , 2015 , 126, 2576-2576	2.2	
597	Significance of Peri-Transplant Dynamics of Minimal Residual Disease (MRD) in Adults with Acute Myeloid Leukemia (AML) in Morphological Remission Undergoing Myeloablative Allogeneic Hematopoietic Cell Transplantation. <i>Blood</i> , 2015 , 126, 173-173	2.2	
596	Prognostic Methylation Markers for Survival in Cytogenetically Normal AML Patients Treated on SWOG Trials. <i>Blood</i> , 2015 , 126, 688-688	2.2	
595	Treosulfan, fludarabine, and 2-Gy total body irradiation followed by allogeneic hematopoietic cell transplantation in patients with myelodysplastic syndrome and acute myeloid leukemia. <i>Biology of Blood and Marrow Transplantation</i> , 2014 , 20, 549-55	4.7	38
594	Unsuccessful diagnostic cytogenetic analysis is a poor prognostic feature in acute myeloid leukaemia. <i>British Journal of Haematology</i> , 2014 , 164, 245-50	4.5	21
593	Outpatient bendamustine and idarubicin for upfront therapy of elderly acute myeloid leukaemia/myelodysplastic syndrome: a phase I/II study using an innovative statistical design. <i>British Journal of Haematology</i> , 2014 , 166, 375-81	4.5	1
592	Multicenter biologic assignment trial comparing reduced-intensity allogeneic hematopoietic cell transplant to hypomethylating therapy or best supportive care in patients aged 50 to 75 with intermediate-2 and high-risk myelodysplastic syndrome: Blood and Marrow Transplant Clinical Trials Network #1102 study rationale, design, and methods. <i>Biology of Blood and Marrow</i>	4.7	18
591	Comorbidity-age index: a clinical measure of biologic age before allogeneic hematopoietic cell transplantation. <i>Journal of Clinical Oncology</i> , 2014 , 32, 3249-56	2.2	273

590	Addition of gemtuzumab ozogamicin to induction chemotherapy in adult patients with acute myeloid leukaemia: a meta-analysis of individual patient data from randomised controlled trials. <i>Lancet Oncology, The</i> , 2014 , 15, 986-96	21.7	410
589	Arsenic trioxide during consolidation for patients with previously untreated low/intermediate risk acute promyelocytic leukaemia may eliminate the need for maintenance therapy. <i>British Journal of Haematology</i> , 2014 , 165, 497-503	4.5	31
588	SWOG S0910: a phase 2 trial of clofarabine/cytarabine/epratuzumab for relapsed/refractory acute lymphocytic leukaemia. <i>British Journal of Haematology</i> , 2014 , 165, 504-9	4.5	66
587	Radiolabeled anti-CD45 antibody with reduced-intensity conditioning and allogeneic transplantation for younger patients with advanced acute myeloid leukemia or myelodysplastic syndrome. <i>Biology of Blood and Marrow Transplantation</i> , 2014 , 20, 1363-8	4.7	47
586	Outcome of patients with abnl(17p) acute myeloid leukemia after allogeneic hematopoietic stem cell transplantation. <i>Blood</i> , 2014 , 123, 2960-7	2.2	51
585	Pretransplant comorbidities predict severity of acute graft-versus-host disease and subsequent mortality. <i>Blood</i> , 2014 , 124, 287-95	2.2	66
584	Unrelated umbilical cord blood transplant for adult acute lymphoblastic leukemia in first and second complete remission: a comparison with allografts from adult unrelated donors. <i>Haematologica</i> , 2014 , 99, 322-8	6.6	70
583	Indications for allogeneic hematopoietic cell transplantation for acute myeloid leukemia in the genomic era. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2014 , e327-33	7.1	7
582	Responsibility for costs associated with clinical trials. <i>Journal of Clinical Oncology</i> , 2014 , 32, 3357-9	2.2	19
581	Arsenic trioxide in front-line therapy of acute promyelocytic leukemia (C9710): prognostic significance of FLT3 mutations and complex karyotype. <i>Leukemia and Lymphoma</i> , 2014 , 55, 1523-32	1.9	41
580	Alternative donor transplantation for adults with acute leukemia. <i>Best Practice and Research in Clinical Haematology</i> , 2014 , 27, 272-7	4.2	17
579	SWOG0919: a Phase 2 study of idarubicin and cytarabine in combination with pravastatin for relapsed acute myeloid leukaemia. <i>British Journal of Haematology</i> , 2014 , 167, 233-7	4.5	31
578	Imatinib 800 mg daily induces deeper molecular responses than imatinib 400 mg daily: results of SWOG S0325, an intergroup randomized PHASE II trial in newly diagnosed chronic phase chronic myeloid leukaemia. <i>British Journal of Haematology</i> , 2014 , 164, 223-32	4.5	46
577	Impact of minimal residual disease, detected by flow cytometry, on outcome of myeloablative hematopoietic cell transplantation for acute lymphoblastic leukemia. <i>Leukemia Research and Treatment</i> , 2014 , 2014, 421723		48
576	Four different regimens of farnesyltransferase inhibitor tipifarnib in older, untreated acute myeloid leukemia patients: North American Intergroup Phase II study SWOG S0432. <i>Leukemia Research</i> , 2014 , 38, 329-33	2.7	20
575	Myeloablative I-131-tositumomab with escalating doses of fludarabine and autologous hematopoietic transplantation for adults age ≥ 60 years with B cell lymphoma. <i>Biology of Blood and Marrow Transplantation</i> , 2014 , 20, 770-5	4.7	18
574	Minimal Residual Disease Detection By Next Generation Sequencing in Adult B-Cell Acute Lymphoblastic Leukemia (ALL) Patients Treated on SWOG Trial S0333. <i>Blood</i> , 2014 , 124, 2399-2399	2.2	2
573	Minimal Residual Disease Does Not Impact Risk of Relapse in Myeloablative Umbilical Cord Blood Transplant Recipients: Comparison with Matched and Mismatched Unrelated Transplants. <i>Blood</i> , 2014 , 124, 2579-2579	2.2	3

572	Role of Comorbidities in Prognostic Evaluation of Outcomes Following Allogeneic Hematopoietic Cell Transplantation (HCT) from HLA-Mismatched (MM) and Umbilical Cord Blood (UCB) Donor Grafts. <i>Blood</i> , 2014 , 124, 2583-2583	2.2	3
571	Infusion of a Non HLA-Matched Off-the-Shelf Ex Vivo Expanded Cord Blood Progenitor Cell Product Following Myeloablative Cord Blood Transplantation Is Safe, Decreases the Time to Hematopoietic Recovery, and Results in Excellent Overall Survival. <i>Blood</i> , 2014 , 124, 46-46	2.2	11
570	Survival after T-Cell Replete Haplo-Identical Related Donor Transplant Using Post-Transplant Cyclophosphamide Compared with Matched Unrelated Donor Transplant for Acute Myeloid Leukemia. <i>Blood</i> , 2014 , 124, 679-679	2.2	3
569	Favorable Outcomes for Older Adolescents and Young Adults (AYA) with Acute Lymphoblastic Leukemia (ALL): Early Results of U.S. Intergroup Trial C10403. <i>Blood</i> , 2014 , 124, 796-796	2.2	72
568	Telomere Length Recovery Strongly Predicts Overall Survival in Acute Promyelocytic Leukemia. <i>Blood</i> , 2014 , 124, 2375-2375	2.2	
567	Effect of Allogeneic Hematopoietic Cell Transplant in First Complete Remission on Post-Relapse CR Rate and Survival in Acute Myeloid Leukemia. <i>Blood</i> , 2014 , 124, 5257-5257	2.2	
566	Empiric Definition of Eligibility Criteria for Clinical Trials in Relapsed/Refractory AML: Analysis of 1,892 Patients from HOVON/SAKK and SWOG. <i>Blood</i> , 2014 , 124, 3676-3676	2.2	
565	Determinants of Fatal Bleeding during Induction Therapy for Acute Promyelocytic Leukemia in the ATRA Era. <i>Blood</i> , 2014 , 124, 948-948	2.2	1
564	Measurement of minimal residual disease before and after myeloablative hematopoietic cell transplantation for acute leukemia. <i>Best Practice and Research in Clinical Haematology</i> , 2013 , 26, 279-84	4.2	22
563	Evaluation of early discharge after hospital treatment of neutropenic fever in acute myeloid leukemia (AML). <i>Leukemia Research Reports</i> , 2013 , 2, 26-8	0.6	2
562	Risk assessment before allogeneic hematopoietic cell transplantation for older adults with acute myeloid leukemia. <i>Expert Review of Hematology</i> , 2013 , 6, 547-62	2.8	23
561	Frequency of allogeneic hematopoietic cell transplantation among patients with high- or intermediate-risk acute myeloid leukemia in first complete remission. <i>Journal of Clinical Oncology</i> , 2013 , 31, 3883-8	2.2	35
560	Outcome of adolescents and young adults with acute myeloid leukemia treated on COG trials compared to CALGB and SWOG trials. <i>Cancer</i> , 2013 , 119, 4170-9	6.4	31
559	Implementing a Death with Dignity program at a comprehensive cancer center. <i>New England Journal of Medicine</i> , 2013 , 368, 1417-24	59.2	76
558	Significance of FAB subclassification of "acute myeloid leukemia, NOS" in the 2008 WHO classification: analysis of 5848 newly diagnosed patients. <i>Blood</i> , 2013 , 121, 2424-31	2.2	75
557	The impact of initial fludarabine therapy on transformation to Richter syndrome or prolymphocytic leukemia in patients with chronic lymphocytic leukemia: analysis of an intergroup trial (CALGB 9011). <i>Leukemia and Lymphoma</i> , 2013 , 54, 252-4	1.9	30
556	A model for prediction of FLT3-ITD and NPM1 (without FLT3-ITD) positivity in patients with newly diagnosed acute myeloid leukaemia. <i>British Journal of Haematology</i> , 2013 , 163, 130-2	4.5	
555	A phase 3 study of gemtuzumab ozogamicin during induction and postconsolidation therapy in younger patients with acute myeloid leukemia. <i>Blood</i> , 2013 , 121, 4854-60	2.2	441

554	Who is the better donor for older hematopoietic transplant recipients: an older-aged sibling or a young, matched unrelated volunteer?. <i>Blood</i> , 2013 , 121, 2567-73	2.2	92
553	Acute myeloid leukemia, version 2.2013. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2013 , 11, 1047-55	7.3	113
552	Retrospective comparison of clofarabine versus fludarabine in combination with high-dose cytarabine with or without granulocyte colony-stimulating factor as salvage therapies for acute myeloid leukemia. <i>Haematologica</i> , 2013 , 98, 114-8	6.6	18
551	Prognostic Significance Of NPM1 mutations In The Absence Of FLT3-ITD in Older Patients With AML: A SWOG Report. <i>Blood</i> , 2013 , 122, 1315-1315	2.2	4
550	Global Hematopoietic Stem Cell Transplantation (HSCT) At One Million: An Achievement Of Pioneers and Foreseeable Challenges For The Next Decade. A Report From The Worldwide Network For Blood and Marrow Transplantation (WBMT). <i>Blood</i> , 2013 , 122, 2133-2133	2.2	5
549	Impact Of Cytarabine Dose In The Induction Regimen On The Outcome Of Patients With Newly Diagnosed Acute Myeloid Leukemia With Or Without NPM1 and/Or FLT3 Mutations: A SWOG and MD Anderson Cancer Center Report. <i>Blood</i> , 2013 , 122, 2686-2686	2.2	1
548	Dose Dependent Enhancement Of Neutrophil Recovery By Infusion Of Notch Ligand Ex Vivo Expanded Cord Blood Progenitors: Results Of a Multi-Center Phase I Trial. <i>Blood</i> , 2013 , 122, 297-297	2.2	4
547	A Phase I Study Of Myeloablative Radioimmunotherapy Using Iodine-131 Anti-CD45 Antibody Followed By Autologous Stem Cell Transplantation For High-Risk B-Cell and T-Cell Non-Hodgkin Lymphoma and Hodgkin Lymphoma. <i>Blood</i> , 2013 , 122, 3333-3333	2.2	1
546	The Addition Of Gemtuzumab Ozogamicin (GO) To Induction Chemotherapy Reduces Relapse and Improves Survival In Patients Without Adverse Risk Karyotype: Results Of An Individual Patient Meta-Analysis Of The Five Randomised Trials. <i>Blood</i> , 2013 , 122, 356-356	2.2	8
545	Mobilization Of Blasts and Leukemia Stem Cells by Anti-CXCR4 Antibody BMS-936564 (MDX 1338) in Patients With Relapsed/Refractory Acute Myeloid Leukemia. <i>Blood</i> , 2013 , 122, 3882-3882	2.2	6
544	Frontline-Treatment Of Acute Lymphoblastic Leukemia (ALL) In Older Adolescents and Young Adults (AYA) Using a Pediatric Regimen Is Feasible: Toxicity Results of the Prospective US Intergroup Trial C10403 (Alliance). <i>Blood</i> , 2013 , 122, 3903-3903	2.2	29
543	Prediction Of CR On Reinduction In Patients With Newly Diagnosed Acute Myeloid Leukemia Given Intensive Induction Regimens: A Report From SWOG and Cleveland Clinic. <i>Blood</i> , 2013 , 122, 3924-3924	2.2	5
542	Evaluation Of Which Patients Get a Second Course Of 3+7 On Cooperative Group Trials For Newly Diagnosed Acute Myeloid Leukemia: A Report From SWOG. <i>Blood</i> , 2013 , 122, 3925-3925	2.2	4
541	Assessment Of The Value Of a Day 14 Bone Marrow In Newly Diagnosed AML. <i>Blood</i> , 2013 , 122, 5002-5002		1
540	Adhesion Of Acute Myeloid Leukemia Blasts To E-Selectin In The Vascular Niche Enhances Their Survival By Mechanisms Such As Wnt Activation. <i>Blood</i> , 2013 , 122, 61-61	2.2	19
539	Efficacy and Safety Of Lower-Dose Glucocorticoids For Initial Treatment Of Acute Graft-Versus-Host Disease: A Randomized Controlled Trial. <i>Blood</i> , 2013 , 122, 703-703	2.2	3
538	The prognostic significance of IRF8 transcripts in adult patients with acute myeloid leukemia. <i>PLoS ONE</i> , 2013 , 8, e70812	3.7	13
537	A Phase II Study Of Tosedostat (TST) In Combination With Either Cytarabine Or Decitabine In Newly Diagnosed Older Patients With Acute Myeloid Leukemia (AML) Or High-Risk Myelodysplastic Syndrome (MDS). <i>Blood</i> , 2013 , 122, 3926-3926	2.2	

536	Proof-Of-Concept Study For Precision Medicine With Chromosome Genomic Array Testing (CGAT) For Drug Sensitivity Screening In Acute Myeloid Leukemia. <i>Blood</i> , 2013 , 122, 2578-2578	2.2	
535	Prediction Of Therapeutic Resistance In Adult Acute Myeloid Leukemia: Analysis Of 4,550 Newly Diagnosed Patients From MRC/NCRI, HOVON/SAKK, SWOG, and MD Anderson Cancer Center. <i>Blood</i> , 2013 , 122, 64-64	2.2	1
534	NUP98/NSD1 Translocation Further Risk-Stratifies Patients With FLT3/ITD In Acute Myeloid Leukemia: A Report From Children's Oncology Group and SWOG. <i>Blood</i> , 2013 , 122, 488-488	2.2	
533	Novel Long-Term Co-Culture Approach Identifies Prognostically Important Heterogeneity Of Stem/Progenitor Cell Involvement In Human Acute Myeloid Leukemia. <i>Blood</i> , 2013 , 122, 1318-1318	2.2	
532	Comparison Of Minimal Residual Disease As Outcome Predictor For AML Patients In First Complete Remission Undergoing Myeloablative Or Nonmyeloablative Allogeneic Hematopoietic Cell Transplantation. <i>Blood</i> , 2013 , 122, 1317-1317	2.2	
531	Alteration Of Cytogenetic Risk Stratification In New Diagnosis Of Leukemia By FISH Testing □ Retrospective Review Of The SWOG Experience. <i>Blood</i> , 2013 , 122, 1383-1383	2.2	
530	Success of allogeneic marrow transplantation for children with severe aplastic anaemia. <i>British Journal of Haematology</i> , 2012 , 158, 120-8	4.5	21
529	Impact of body-mass index on the outcome of adult patients with acute myeloid leukemia. <i>Haematologica</i> , 2012 , 97, 1401-4	6.6	52
528	Reduced-intensity conditioning transplantation in acute leukemia: the effect of source of unrelated donor stem cells on outcomes. <i>Blood</i> , 2012 , 119, 5591-8	2.2	113
527	The Dynamic International Prognostic Scoring System for myelofibrosis predicts outcomes after hematopoietic cell transplantation. <i>Blood</i> , 2012 , 119, 2657-64	2.2	116
526	Acute myeloid leukemia stem cells and CD33-targeted immunotherapy. <i>Blood</i> , 2012 , 119, 6198-208	2.2	217
525	Long-term outcomes after transplantation of HLA-identical related G-CSF-mobilized peripheral blood mononuclear cells versus bone marrow. <i>Blood</i> , 2012 , 119, 2675-8	2.2	49
524	Blood consult: monosomal karyotype acute myeloid leukemia. <i>Blood</i> , 2012 , 119, 5659-60	2.2	1
523	Retrospective. E. Donnall Thomas (1920-2012). <i>Science</i> , 2012 , 338, 1163	33.3	3
522	Comparative outcomes of donor graft CD34+ selection and immune suppressive therapy as graft-versus-host disease prophylaxis for patients with acute myeloid leukemia in complete remission undergoing HLA-matched sibling allogeneic hematopoietic cell transplantation. <i>Journal of Clinical Oncology</i> , 2012 , 30, 3194-201	2.2	124
521	Pretransplantation therapy with azacitidine vs induction chemotherapy and posttransplantation outcome in patients with MDS. <i>Biology of Blood and Marrow Transplantation</i> , 2012 , 18, 1211-8	4.7	137
520	Anti-T cell antibodies as part of the preparative regimen in hematopoietic cell transplantation--a debate. <i>Biology of Blood and Marrow Transplantation</i> , 2012 , 18, S111-5	4.7	10
519	Improved outcomes with allogeneic hematopoietic cell transplantation. <i>Best Practice and Research in Clinical Haematology</i> , 2012 , 25, 465-71	4.2	3

518	Prognostic implications of additional chromosome abnormalities among patients with de novo acute promyelocytic leukemia with t(15;17). <i>Medical Oncology</i> , 2012 , 29, 2095-101	3.7	13
517	Prognostic impact of discordant results from cytogenetics and flow cytometry in patients with acute myeloid leukemia undergoing hematopoietic cell transplantation. <i>Cancer</i> , 2012 , 118, 2411-9	6.4	23
516	Impact of residual normal metaphases in core binding factor acute myeloid leukemia. <i>Cancer</i> , 2012 , 118, 2420-3	6.4	6
515	Phase II trial of vorinostat and gemtuzumab ozogamicin as induction and post-remission therapy in older adults with previously untreated acute myeloid leukemia. <i>Haematologica</i> , 2012 , 97, 739-42	6.6	24
514	Gemtuzumab ozogamicin: time to resurrect?. <i>Journal of Clinical Oncology</i> , 2012 , 30, 3921-3	2.2	84
513	NCCN Clinical Practice Guidelines Acute myeloid leukemia. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2012 , 10, 984-1021	7.3	194
512	Declining Rates of Treatment-Related Mortality in Patients with Newly Diagnosed Acute Myeloid Leukemia (AML) Given Intensive Induction Regimens: A Report From the Southwest Oncology Group (SWOG) and MD Anderson Cancer Center (MDA). <i>Blood</i> , 2012 , 120, 129-129	2.2	3
511	The Relation of Clinical Response and Minimal Residual Disease and Their Prognostic Impact On Outcome in Acute Myeloid Leukemia. <i>Blood</i> , 2012 , 120, 1418-1418	2.2	2
510	Single-Cell Network Profiling (SCNP)-Based Classifier to Predict Response to Induction Therapy in Elderly Patients with Acute Myeloid Leukemia (AML): Validation in Two Independent Sample Sets From ECOG and SWOG Trials.. <i>Blood</i> , 2012 , 120, 2489-2489	2.2	1
509	Southwest Oncology Group Study S0910: A Phase 2 Trial of Clofarabine/ Cytarabine/ Epratuzumab for Relapsed/ Refractory Acute Lymphocytic Leukemia.. <i>Blood</i> , 2012 , 120, 2603-2603	2.2	6
508	Who Participates in an Adult Cooperative Group Trial for Adolescent and Young Adults (AYAs)? Baseline Demographic and Psychosocial Characteristics of AYAs Enrolled On Intergroup Trial C10403 for Acute Lymphoblastic Leukemia (ALL). <i>Blood</i> , 2012 , 120, 3535-3535	2.2	1
507	A Phase II Trial of Azacitidine (NSC-102816) and Gemtuzumab Ozogamicin (NSC-720568) As Induction and Post-Remission Therapy in Patients of Age 60 and Older with Previously Untreated Non-M3 Acute Myeloid Leukemia (SWOG S0703): Report On the Poor Risk Patients. <i>Blood</i> , 2012 , 120, 4164-4164	2.2	3
506	Hematopoietic Bone Marrow Transplantation (BMT) for Patients with High-Risk Acute Myeloid Leukemia (AML), Acute Lymphoblastic Leukemia (ALL), or Myelodysplastic Syndrome (MDS) Using HLA-Haploidentical Related Donors: A Trial Using Radiolabeled Anti-CD45 Antibody Combined with Immunosuppression Before and After BMT. <i>Blood</i> , 2012 , 120, 4164-4164	2.2	3
505	Impact of Minimal Residual Disease, As Detected by Multiparametric Flow Cytometry Pre and Post Transplantation, On Outcome of Myeloablative Hematopoietic Cell Transplantation for Acute Lymphoblastic Leukemia. <i>Blood</i> , 2012 , 120, 592-592	2.2	1
504	Prospective Phase II Multicenter Study of Conditioning with Treosulfan, Fludarabine and Low-Dose (2 Gy) Total Body Irradiation Followed by Hematopoietic Cell Transplantation From Related or Unrelated Donors for Acute Myeloid Leukemia and High-Risk Myelodysplastic Syndrome. <i>Blood</i> , 2012 , 120, 963-963	2.2	1
503	To transplant or not to transplant for adult acute myeloid leukemia: an ever-evolving decision. <i>Clinical Advances in Hematology and Oncology</i> , 2012 , 10, 655-62	0.6	
502	Quantitative Significance of Minimal Residual Disease Before Myeloablative Allogeneic Hematopoietic Cell Transplantation for Acute Myeloid Leukemia in First and Second Complete Remission. <i>Blood</i> , 2012 , 120, 655-655	2.2	
501	RNA-Sequencing Unveils Cryptic Fusions in Patients with Acute Myeloid Leukemia. <i>Blood</i> , 2012 , 120, 1278-1278	2.2	

500	A Phase II Trial of Myeloablative I-131-Tositumomab, Etoposide and Cyclophosphamide Followed by Autologous Transplantation for B-Cell Non-Hodgkin's Lymphoma. <i>Blood</i> , 2012 , 120, 811-811	2.2	
499	NCI Common Toxicity Criteria and Mortality After Chemotherapy for Acute Myeloid Leukemia (AML). <i>Blood</i> , 2012 , 120, 1479-1479	2.2	
498	Prognostic Significance of the French-American-British (FAB) Morphologic Subclassification of Acute Myeloid Leukemia, Not Otherwise Specified in the 2008 WHO Classification: Analysis of 5,848 Newly Diagnosed Patients From HOVON, MRC/NCRI, SWOG, and MD Anderson Cancer Center. <i>Blood</i> , 2012 , 120, 530-540	2.2	
497	A Phase II Trial Combining Radiolabeled Anti-CD45 Antibody with Fludarabine and Low-Dose Total Body Irradiation (TBI) Followed by Related or Unrelated Hematopoietic Cell Transplantation for Patients Under Age 50 with Advanced Acute Myeloid Leukemia (AML) or High-Risk Myelodysplastic Syndrome (MDS). <i>Blood</i> , 2012 , 120, 1924-1934	2.2	
496	Probability of Eventual CR After Course 1 of Induction Therapy for Newly-Diagnosed AML As a Function of Platelet and Neutrophil Recovery.. <i>Blood</i> , 2012 , 120, 2598-2598	2.2	
495	Myeloablative Umbilical Cord Blood Transplantation for Hematologic Malignancies Is Comparable to Unrelated Donor Transplantation: A Retrospective Single-Center Study. <i>Blood</i> , 2012 , 120, 1995-1995	2.2	
494	Morphology Vs. Multiparameter Flow Cytometry in Evaluation of AML in Cerebrospinal Fluid (CSF).. <i>Blood</i> , 2012 , 120, 2499-2499	2.2	
493	Multicenter Phase 2 Trial of G-CSF Priming, Clofarabine, and High Dose Cytarabine (GCLAC) for Newly Diagnosed Acute Myeloid Leukemia, Advanced Myelodysplastic Syndrome or Advanced Myeloproliferative Neoplasm. <i>Blood</i> , 2012 , 120, 3594-3594	2.2	
492	A Scoring System for Prediction of FLT3-ITD Positivity in Patients with Newly Diagnosed Acute Myeloid Leukemia.. <i>Blood</i> , 2012 , 120, 2590-2590	2.2	
491	Safety and Efficacy of Bendamustine and Idarubicin in Combination Therapy for Patients Age 60 with Untreated Acute Myeloid Leukemia and High-Risk Myelodysplastic Syndrome [Results From a Phase I/II Adaptive Design Study.. <i>Blood</i> , 2012 , 120, 2622-2622	2.2	
490	The role of hematopoietic cell transplantation as therapy for myelodysplasia. <i>Best Practice and Research in Clinical Haematology</i> , 2011 , 24, 541-7	4.2	5
489	Conditioning with treosulfan and fludarabine followed by allogeneic hematopoietic cell transplantation for high-risk hematologic malignancies. <i>Biology of Blood and Marrow Transplantation</i> , 2011 , 17, 341-50	4.7	80
488	Allogeneic hematopoietic cell transplantation for chronic myelomonocytic leukemia: relapse-free survival is determined by karyotype and comorbidities. <i>Biology of Blood and Marrow Transplantation</i> , 2011 , 17, 908-15	4.7	91
487	Generic immunosuppressants in hematopoietic cell transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2011 , 17, 285-90	4.7	11
486	Allogeneic hematopoietic cell transplantation with full-intensity conditioning for adult acute lymphoblastic leukemia: results from a single center, 1998-2006. <i>Biology of Blood and Marrow Transplantation</i> , 2011 , 17, 1187-95	4.7	20
485	A phase I/II study of chemotherapy followed by donor lymphocyte infusion plus interleukin-2 for relapsed acute leukemia after allogeneic hematopoietic cell transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2011 , 17, 1308-15	4.7	15
484	A retrospective comparison of tacrolimus versus cyclosporine with methotrexate for immunosuppression after allogeneic hematopoietic cell transplantation with mobilized blood cells. <i>Biology of Blood and Marrow Transplantation</i> , 2011 , 17, 1088-92	4.7	30
483	Preparative regimens and ageism. <i>Biology of Blood and Marrow Transplantation</i> , 2011 , 17, 1419-20	4.7	11

482	Comparative analysis of risk factors for acute graft-versus-host disease and for chronic graft-versus-host disease according to National Institutes of Health consensus criteria. <i>Blood</i> , 2011 , 117, 3214-9	2.2	420
481	Identifying older patients with acute myeloid leukemia who may be candidates for reduced-intensity hematopoietic cell transplantation. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2011 , 9, 319-29; quiz 330	7.3	3
480	Indications for and current results with allogeneic hematopoietic cell transplantation in patients with myelofibrosis. <i>Blood</i> , 2011 , 117, 7185	2.2	17
479	Outpatient management following intensive induction chemotherapy for myelodysplastic syndromes and acute myeloid leukemia: a pilot study. <i>Haematologica</i> , 2011 , 96, 914-7	6.6	27
478	Influence of residual normal metaphases in acute myeloid leukemia patients with monosomal karyotype. <i>Haematologica</i> , 2011 , 96, 631-2	6.6	10
477	Acute myeloid leukemia. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2011 , 9, 280-317	7.3	45
476	Clofarabine with high dose cytarabine and granulocyte colony-stimulating factor (G-CSF) priming for relapsed and refractory acute myeloid leukaemia. <i>British Journal of Haematology</i> , 2011 , 155, 182-9	4.5	68
475	Infections in relapsed or refractory acute myeloid leukemia patients given clofarabine+cytarabine. <i>Leukemia Research</i> , 2011 , 35, e164-6	2.7	4
474	Hematopoietic cell transplantation with autologous cord blood in patients with severe aplastic anemia: an opportunity to revisit the controversy regarding cord blood banking for private use. <i>Pediatric Blood and Cancer</i> , 2011 , 56, 1009-12	3	28
473	Impact of pretransplantation minimal residual disease, as detected by multiparametric flow cytometry, on outcome of myeloablative hematopoietic cell transplantation for acute myeloid leukemia. <i>Journal of Clinical Oncology</i> , 2011 , 29, 1190-7	2.2	270
472	Prediction of early death after induction therapy for newly diagnosed acute myeloid leukemia with pretreatment risk scores: a novel paradigm for treatment assignment. <i>Journal of Clinical Oncology</i> , 2011 , 29, 4417-23	2.2	230
471	Multi-Institutional Validation of the Predictive Power of the Hematopoietic Cell Transplantation Comorbidity Index (HCT-CI) for HCT Outcomes. <i>Blood</i> , 2011 , 118, 145-145	2.2	4
470	Impact of Pre-Transplant Comorbidities on the Rate of- and Mortality-Following Acute Graft-Versus-Host Disease (GVHD) After Allogeneic Hematopoietic Cell Transplantation (HCT). <i>Blood</i> , 2011 , 118, 156-156	2.2	1
469	Prognostic Significance of FLT3 and NPM1 Mutations in Adults of Age 18-80 with De Novo Acute Myeloid Leukemia (AML) on SWOG S0106 Study: A Study by FHCRC and SWOG. <i>Blood</i> , 2011 , 118, 2520-2520	2.2	2
468	Adding Mercaptopurine and Methotrexate to Alternate Week ATRA Maintenance Therapy Does Not Improve the Outcome for Adults with Acute Promyelocytic Leukemia (APL) in First Remission: Results From North American Leukemia Intergroup Trial C9710. <i>Blood</i> , 2011 , 118, 258-258	2.2	5
467	Impact of Age on Outcomes Following Initial Therapy with Various Chemotherapy and Chemoimmunotherapy Regimens in Patients with Chronic Lymphocytic Leukemia (CLL): Results of CALGB Studies. <i>Blood</i> , 2011 , 118, 289-289	2.2	2
466	Transplantation of Peripheral Blood Cells As Compared with Bone Marrow From HLA-Identical Related Donors Is Associated with Superior Long-Term Outcomes. <i>Blood</i> , 2011 , 118, 319-319	2.2	3
465	Prevalence and Clinical Implications of IDH2 R140 and R172 Mutations in Older Adults with AML: A Report From SWOG,. <i>Blood</i> , 2011 , 118, 3516-3516	2.2	0

464	Infusion of Off-the-shelf Third Party Ex Vivo Expanded Cord Blood Progenitor Cells As Supportive Care Following Clofarabine with High Dose Cytarabine and Granulocyte Colony-Stimulating Factor Priming for the Treatment of AML. <i>Blood</i> , 2011 , 118, 3640-3640	2.2	1
463	Interaction of Age and Comorbidities and Their Impacts on Hematopoietic Cell Transplantation (HCT) Outcomes. <i>Blood</i> , 2011 , 118, 665-665	2.2	2
462	Impact of the Novel 5-Group Cytogenetic Risk Classification of MDS on Outcome After Allogeneic Hematopoietic Cell Transplantation (HCT). <i>Blood</i> , 2011 , 118, 666-666	2.2	2
461	Late Relapses Following All-Trans Retinoic Acid for Acute Promyelocytic Leukemia Are Uncommon, Respond Well to Salvage Therapy and Occur Independently of Prognostic Factors At Diagnosis: Long-Term Follow-up of North American Intergroup Study I0129. <i>Blood</i> , 2011 , 118, 83-83	2.2	2
460	Survival After Failure of Initial Therapy for Newly-Diagnosed or Relapsed/Refractory AML At An Academic Center: Subsequent Clinical Trial Vs. Not. <i>Blood</i> , 2011 , 118, 1497-1497	2.2	
459	Phase 2 Trial of G-CSF Priming, Clofarabine, and High Dose Cytarabine (GCLAC) for the Treatment of Newly Diagnosed Acute Myeloid Leukemia (AML) or Advanced Myelodysplastic Syndrome or Advanced Myeloproliferative Neoplasm. <i>Blood</i> , 2011 , 118, 3617-3617	2.2	
458	Response to High Dose Cytarabine (HIDAC) As First Salvage for Relapsed Acute Lymphocytic Leukemia in Patients Receiving HIDAC As Initial Therapy. <i>Blood</i> , 2011 , 118, 2594-2594	2.2	
457	Novel Dual E-Selectin-CXCR4 Inhibitors Mobilize Human Acute Myeloid Leukemia (AML) Cells in the NODscid IL2R β Xenograft and Confer Susceptibility to Cytarabine. <i>Blood</i> , 2011 , 118, 579-579	2.2	
456	Probability of Eventual CR After Course 1 of Induction Therapy for Newly-Diagnosed AML As a Function of Speed of Neutrophil and Platelet Recovery. <i>Blood</i> , 2011 , 118, 1498-1498	2.2	
455	KIT Mutations Are Rare Among Elderly AML Patients: A SWOG Report. <i>Blood</i> , 2011 , 118, 2510-2510	2.2	
454	Outcome and Prevalence of Hyperdiploidy and Hypodiploidy in Adults with Newly Diagnosed Acute Lymphocytic Leukemia: A SWOG Study. <i>Blood</i> , 2011 , 118, 2555-2555	2.2	
453	Impact of Comorbidities on Early and Late Mortalities After Allogeneic Hematopoietic Cell Transplantation (HCT). <i>Blood</i> , 2011 , 118, 326-326	2.2	
452	DNMT3A Mutations Independently Predict Poor Outcome in Older AML Patients: A SWOG Report. <i>Blood</i> , 2011 , 118, 3519-3519	2.2	
451	Identification of Differential Methylation Markers Among Cytogenetic Risk Groups of Acute Myeloid Leukemia. <i>Blood</i> , 2011 , 118, 1464-1464	2.2	
450	A Phase I Study of Myeloablative I-131-Anti CD-20 (Tositumomab) Radioimmunotherapy with Escalating Doses of Fludarabine Followed by Autologous Hematopoietic Stem Cell Transplantation (ASCT) for Adults \geq 60 Years of Age with High-Risk or Relapsed/Refractory B-Cell Lymphoma. <i>Blood</i> , 2011 , 118, 663-663	2.2	1
449	The CXCR4 Inhibitor Plerixafor Effectively Mobilizes Primary AML in NODscid IL2R β Xenografts and Markedly Reduces but Does Not Eradicate Leukemia in Combination with Cytarabine +/- Clofarabine Chemotherapy. <i>Blood</i> , 2011 , 118, 1432-1432	2.2	
448	Prognostic Import of French-American-British (FAB) System As Embedded in 2008 Revision of World Health Organization Classification of AML: Review of SWOG Data. <i>Blood</i> , 2011 , 118, 1446-1446	2.2	
447	Sequential phase II Southwest Oncology Group studies (S0112 and S0301) of daunorubicin and cytarabine by continuous infusion, without and with ciclosporin, in older patients with previously untreated acute myeloid leukaemia. <i>British Journal of Haematology</i> , 2010 , 148, 48-58	4.5	24

446	Southwest Oncology Group Study S0530: a phase 2 trial of clofarabine and cytarabine for relapsed or refractory acute lymphocytic leukaemia. <i>British Journal of Haematology</i> , 2010 , 151, 430-4	4.5	49
445	Effect of complete remission and responses less than complete remission on survival in acute myeloid leukemia: a combined Eastern Cooperative Oncology Group, Southwest Oncology Group, and M. D. Anderson Cancer Center Study. <i>Journal of Clinical Oncology</i> , 2010 , 28, 1766-71	2.2	145
444	Nonmyeloablative allogeneic hematopoietic cell transplantation in patients with acute myeloid leukemia. <i>Journal of Clinical Oncology</i> , 2010 , 28, 2859-67	2.2	163
443	Life expectancy in patients surviving more than 5 years after hematopoietic cell transplantation. <i>Journal of Clinical Oncology</i> , 2010 , 28, 1011-6	2.2	257
442	Dose intensity of preparative regimens for acute myeloid leukemia - one-size-fits-all or tailor-made?. <i>Best Practice and Research in Clinical Haematology</i> , 2010 , 23, 509-17	4.2	8
441	Impact of recipient statin treatment on graft-versus-host disease after allogeneic hematopoietic cell transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2010 , 16, 1463-6	4.7	33
440	Reduced mortality after allogeneic hematopoietic-cell transplantation. <i>New England Journal of Medicine</i> , 2010 , 363, 2091-101	59.2	1102
439	Therapy of relapsed leukemia after allogeneic hematopoietic cell transplantation with T cells specific for minor histocompatibility antigens. <i>Blood</i> , 2010 , 115, 3869-78	2.2	188
438	Does microgranular variant morphology of acute promyelocytic leukemia independently predict a less favorable outcome compared with classical M3 APL? A joint study of the North American Intergroup and the PETHEMA Group. <i>Blood</i> , 2010 , 116, 5650-9	2.2	29
437	Donor statin treatment protects against severe acute graft-versus-host disease after related allogeneic hematopoietic cell transplantation. <i>Blood</i> , 2010 , 115, 1288-95	2.2	45
436	Allogeneic hematopoietic cell transplantation for hematologic malignancy: relative risks and benefits of double umbilical cord blood. <i>Blood</i> , 2010 , 116, 4693-9	2.2	397
435	Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet. <i>Blood</i> , 2010 , 115, 453-74	2.2	2483
434	Influence of Residual Normal Metaphases In Patients with Monosomal Karyotype.. <i>Blood</i> , 2010 , 116, 1671-1671	2.2	1
433	Over-Expression of Novel IRF8 Splice Variants Is Associated with a Significant Decrease In Relapse-Free Survival In Adult AML Patients.. <i>Blood</i> , 2010 , 116, 1679-1679	2.2	1
432	Quantitative Effect of Age In Predicting Empirically-Defined Treatment-Related Mortality and Resistance In Newly Diagnosed AML: Case Against Age Alone as Primary Determinant of Treatment Assignment. <i>Blood</i> , 2010 , 116, 2191-2191	2.2	8
431	International Working Group Scores Predict Post-Transplant Outcomes In Patients with Myelofibrosis. <i>Blood</i> , 2010 , 116, 3085-3085	2.2	4
430	A Phase II Study of Lenalidomide for Previously Untreated Deletion (del) 5q Acute Myeloid Leukemia (AML) Patients Age 60 or Older Who Are Not Candidates for Remission Induction Chemotherapy (Southwest Oncology Group Study S0605). <i>Blood</i> , 2010 , 116, 332-332	2.2	2
429	A Relapse Risk Score to Predict Acute Myeloid Leukemia Relapse After Nonmyeloablative Allogeneic Hematopoietic Cell Transplantation Based on Pre-Transplant Variables.. <i>Blood</i> , 2010 , 116, 3450-3450	2.2	1

428	Effect of Peripheral Blood Stem Cell (PBSC) Graft Composition on Graft Versus Host Disease (GVHD) and Mortality After Allogeneic Transplantation. <i>Blood</i> , 2010 , 116, 676-676	2.2	2
427	Reduced Intensity Conditioning (RIC) Transplantation In Acute Leukemia: The Effect of Source of Unrelated Donor Stem Cells on Outcomes. <i>Blood</i> , 2010 , 116, 908-908	2.2	1
426	Clonal Markers In Relapsed Acute Promyelocytic Leukemia (APL): Clinicopathological Associations and Relation to All-Trans Retinoic Acid (ATRA) Treatment on Intergroup Phase III Trial C9710.. <i>Blood</i> , 2010 , 116, 1038-1038	2.2	
425	Evaluation of Early Discharge After Hospital Treatment of Neutropenic Fever In Acute Myelogenous Leukemia (AML).. <i>Blood</i> , 2010 , 116, 3806-3806	2.2	
424	Increased Incidence of Therapy Related Myeloid Neoplasia (t-MN) After Initial Therapy for CLL with Fludarabine-Cyclophosphamide (FC) Vs Fludarabine (F): Long-Term Follow-up of US Intergroup Study E2997. <i>Blood</i> , 2010 , 116, 924-924	2.2	
423	Prognostic Implications of the IDH1 synonymous SNP rs11554137 In Pediatric and Adult AML: a Children's Oncology Group and Southwest Oncology Group Study. <i>Blood</i> , 2010 , 116, 2737-2737	2.2	1
422	Analysis of CRLF2/JAK Expression and Mutation Status In Adult ALL Patients. <i>Blood</i> , 2010 , 116, 758-758	2.2	
421	CD38 Status of CD34+ Myeloblasts, but Not Side Population (SP) Frequency, Predicts Initial Response to Induction Therapy In Patients with Newly Diagnosed Acute Myeloid Leukemia (AML).. <i>Blood</i> , 2010 , 116, 1056-1056	2.2	
420	Early Discharge and Outpatient Management of Adult Patients Following Intensive Induction Chemotherapy for MDS and Non-APL AML: A Pilot Study. <i>Blood</i> , 2010 , 116, 2161-2161	2.2	
419	Association of Graft-Versus-Host Disease and Immunosuppressive Treatment with Risks of Recurrent Malignancy and Mortality After Allogeneic Hematopoietic Cell Transplantation. <i>Blood</i> , 2010 , 116, 218-218	2.2	
418	A Retrospective Comparison of Tacrolimus Vs. Cyclosporine for Immunosuppression After Allogeneic Hematopoietic Cell Transplantation with G-CSF-Mobilized Blood Cells. <i>Blood</i> , 2010 , 116, 2319-2319	2.2	
417	Multivariate Analysis of Response and Survival After Treatment with Clofarabine, Cytarabine and G-CSF Priming (GCLAC) In Relapsed/Refractory Acute Myeloid Leukemia (AML): Comparison with Prior Experience Using Fludarabine and Cytarabine Combination Regimens.. <i>Blood</i> , 2010 , 116, 1065-1065	2.2	
416	Clinical and Functional Relevance of Interactions Between the Bone Marrow Stromal Microenvironment and Primary Human Acute Myeloid Leukemia (AML) Cells. <i>Blood</i> , 2010 , 116, 2756-2756	2.2	
415	Allogeneic stem cell transplantation for acute myeloid leukemia in first complete remission: systematic review and meta-analysis of prospective clinical trials. <i>JAMA - Journal of the American Medical Association</i> , 2009 , 301, 2349-61	27.4	612
414	Pretargeted radioimmunotherapy using anti-CD45 monoclonal antibodies to deliver radiation to murine hematolymphoid tissues and human myeloid leukemia. <i>Cancer Research</i> , 2009 , 69, 185-92	10.1	21
413	Treatment of children with acute promyelocytic leukemia: results of the first North American Intergroup trial INT0129. <i>Pediatric Blood and Cancer</i> , 2009 , 53, 1005-10	3	36
412	Cord blood transplantation for haematological malignancies: conditioning regimens, double cord transplant and infectious complications. <i>British Journal of Haematology</i> , 2009 , 147, 207-16	4.5	46
411	Optimising the conditioning regimen for acute myeloid leukaemia. <i>Best Practice and Research in Clinical Haematology</i> , 2009 , 22, 543-50	4.2	24

410	Longitudinal assessment of morbidity and acute graft-versus-host disease after allogeneic hematopoietic cell transplantation: retrospective analysis of a multicenter phase III study. <i>Biology of Blood and Marrow Transplantation</i> , 2009 , 15, 749-56	4.7	14
409	Low relapse without excessive transplant-related mortality following myeloablative cord blood transplantation for acute leukemia in complete remission: a matched cohort analysis. <i>Biology of Blood and Marrow Transplantation</i> , 2009 , 15, 1122-9	4.7	48
408	Structural and functional alterations of FLT3 in acute myeloid leukemia. <i>Clinical Cancer Research</i> , 2009 , 15, 4263-9	12.9	169
407	Allogeneic hematopoietic cell transplantation after conditioning with 131I-anti-CD45 antibody plus fludarabine and low-dose total body irradiation for elderly patients with advanced acute myeloid leukemia or high-risk myelodysplastic syndrome. <i>Blood</i> , 2009 , 114, 5444-53	2.2	137
406	Very late antigen-4 function of myeloblasts correlates with improved overall survival for patients with acute myeloid leukemia. <i>Blood</i> , 2009 , 113, 866-74	2.2	55
405	Initial therapy of acute graft-versus-host disease with low-dose prednisone does not compromise patient outcomes. <i>Blood</i> , 2009 , 113, 2888-94	2.2	100
404	Long-term outcome of patients with multiple myeloma after autologous hematopoietic cell transplantation and nonmyeloablative allografting. <i>Blood</i> , 2009 , 113, 3383-91	2.2	87
403	Thyroid function following hematopoietic cell transplantation in children: 30 years' experience. <i>Blood</i> , 2009 , 113, 306-8	2.2	110
402	G-CSF Priming, Clofarabine and High Dose Cytarabine (GCLAC) for Relapsed or Refractory Acute Myeloid Leukemia (AML).. <i>Blood</i> , 2009 , 114, 2068-2068	2.2	3
401	Southwest Oncology Group Study S0530: A Phase 2 Trial of Clofarabine/ Cytarabine for Relapsed/ Refractory Acute Lymphocytic Leukemia.. <i>Blood</i> , 2009 , 114, 3094-3094	2.2	2
400	Risk Factors for the Development of Acute and National Institute of Health (NIH) Chronic Graft-Versus-Host Disease (GVHD).. <i>Blood</i> , 2009 , 114, 345-345	2.2	2
399	Long-Term Survival Analysis of the North American Intergroup Study C9011 Comparing Fludarabine (F) and Chlorambucil (C) in Previously Untreated Patients with Chronic Lymphocytic Leukemia (CLL).. <i>Blood</i> , 2009 , 114, 536-536	2.2	15
398	Low Albumin, High Ferritin, and Thrombocytopenia Before Transplant Predict Non-Relapse Mortality (NRM) Independent of the Hematopoietic Cell Transplantation Comorbidity Index (HCT-CI).. <i>Blood</i> , 2009 , 114, 651-651	2.2	7
397	Reduced Relapse and Similar Progression-Free Survival After Double Umbilical Cord Blood Transplantation (DUCBT): Comparison of Outcomes Between Sibling, Unrelated Adult and Unrelated DUCB Hematopoietic Stem Cell (HSC) Donors.. <i>Blood</i> , 2009 , 114, 662-662	2.2	3
396	Preliminary Results of Southwest Oncology Group Study S0106: An International Intergroup Phase 3 Randomized Trial Comparing the Addition of Gemtuzumab Ozogamicin to Standard Induction Therapy Versus Standard Induction Therapy Followed by a Second Randomization to	2.2	94
395	Post-Consolidation Gemtuzumab Ozogamicin Versus No Additional Therapy for Previously Nonmyeloablative Allogeneic HCT From Unrelated Donors for Multiple Myeloma (MM).. <i>Blood</i> , 2009 , 114, 3391-3391	2.2	
394	Frequency of Allogeneic Stem Cell Transplant(SCT) in Patients Presenting with Newly-Diagnosed AML or AML at Time of First Salvage Therapy.. <i>Blood</i> , 2009 , 114, 4332-4332	2.2	
393	Adhesion Receptor Expression by Acute Myeloid Leukemia (AML) Bone Marrow Derived or Circulating Blasts and AML Stem Cells: The Key to Overcoming Chemoresistance.. <i>Blood</i> , 2009 , 114, 2658-2658 ⁰	2.2	

392	Anti-CD45 Ab Pretargeted Radioimmunotherapy Using An Alpha Emitting Radionuclide (213Bi) Delivers Selective Radiation to Human Myeloid Leukemias in a Mouse Xenograft Model and Results in High Rates of Complete Remission and Long Term Survival.. <i>Blood</i> , 2009 , 114, 1035-1035	2.2	
391	Does histologic grading of inflammation in bone marrow predict the response of aplastic anaemia patients to antithymocyte globulin therapy?. <i>British Journal of Haematology</i> , 2008 , 67, 261-266	4.5	
390	Incorporating hematopoietic cell transplantation (HCT) into the management of adults aged under 60 years with acute myeloid leukemia (AML). <i>Best Practice and Research in Clinical Haematology</i> , 2008 , 21, 85-92	4.2	21
389	What is the impact of hematopoietic cell transplantation (HCT) for older adults with acute myeloid leukemia (AML)?. <i>Best Practice and Research in Clinical Haematology</i> , 2008 , 21, 667-75	4.2	18
388	Sirolimus in combination with cyclosporine or tacrolimus plus methotrexate for prevention of graft-versus-host disease following hematopoietic cell transplantation from unrelated donors. <i>Biology of Blood and Marrow Transplantation</i> , 2008 , 14, 531-7	4.7	42
387	Pretransplant neutropenia is associated with poor-risk cytogenetic features and increased infection-related mortality in patients with myelodysplastic syndromes. <i>Biology of Blood and Marrow Transplantation</i> , 2008 , 14, 799-806	4.7	20
386	Hematopoietic cell transplantation for non-Hodgkin's lymphoma: yesterday, today, and tomorrow. <i>Journal of Clinical Oncology</i> , 2008 , 26, 2927-9	2.2	16
385	Impact of cytogenetics on the outcome of adult acute lymphoblastic leukemia: results of Southwest Oncology Group 9400 study. <i>Blood</i> , 2008 , 111, 2563-72	2.2	166
384	Simultaneously targeting CD45 significantly increases cytotoxicity of the anti-CD33 immunoconjugate, gemtuzumab ozogamicin, against acute myeloid leukemia (AML) cells and improves survival of mice bearing human AML xenografts. <i>Blood</i> , 2008 , 111, 4813-6	2.2	13
383	Eradication of disseminated leukemia in a syngeneic murine leukemia model using pretargeted anti-CD45 radioimmunotherapy. <i>Blood</i> , 2008 , 111, 2261-8	2.2	31
382	Nonmyeloablative Allogeneic Hematopoietic Cell Transplantation in Patients with De Novo and Secondary Acute Myeloid Leukemia. <i>Blood</i> , 2008 , 112, 149-149	2.2	4
381	The Pitfalls of Early Publication of Data in Acute Myeloid Leukemia: A Report from the Eastern Cooperative Oncology Group (ECOG).. <i>Blood</i> , 2008 , 112, 1952-1952	2.2	3
380	Phase I Trial of Clofarabine and High Dose Cytarabine with G-CSF Priming (G-CLAC) for Relapsed or Refractory Acute Myeloid Leukemia. <i>Blood</i> , 2008 , 112, 2964-2964	2.2	1
379	Impact of Pre-Transplant Minimal Residual Disease Assessed by Flow Cytometry on Outcome Following Myeloablative Hematopoietic Cell Transplantation for Patients with AML-CR1.. <i>Blood</i> , 2008 , 112, 3253-3253	2.2	4
378	Treatment-Related Mortality and Relapse Rate from Time of Initiation of Post-Remission Therapy for Patients Receiving Allogeneic Transplantation, Autologous Transplantation or Intensive Chemotherapy: A Report from the Eastern Cooperative Oncology Group (ECOG). <i>Blood</i> , 2008 , 112, 49-49	2.2	3
377	Oral Small Molecule Inhibitor of VLA-4 Overcomes Adhesion Mediated Chemotherapy Resistance of Acute Myeloid Leukemia (AML) Blasts in Vitro, without Impairment of Normal Blood Cell Recovery When Combined with Chemotherapy in Vivo. <i>Blood</i> , 2008 , 112, 858-858	2.2	4
376	Decreased Relapse Rates without Excessive Transplant Related Mortality Following Cord Blood Transplantation (CBT): A Matched Cohort Analysis Comparing Myeloablative Cord, Matched Unrelated, and Mismatched Unrelated Donor Transplants.. <i>Blood</i> , 2008 , 112, 968-968	2.2	2
375	Tandem Auto/AlloHCT for Newly Diagnosed Multiple Myeloma (MM) Patients.. <i>Blood</i> , 2008 , 112, 1130-1130	2.2	30

374	Adult Cord Blood Transplantation (CBT) Vs. Unrelated Donor Transplantation: A Cost Comparison. <i>Blood</i> , 2008 , 112, 2383-2383	2.2	
373	Comorbidity and disease status based risk stratification of outcomes among patients with acute myeloid leukemia or myelodysplasia receiving allogeneic hematopoietic cell transplantation. <i>Journal of Clinical Oncology</i> , 2007 , 25, 4246-54	2.2	320
372	Hematopoietic cell transplantation from unrelated donors for treatment of patients with acute myeloid leukemia in first complete remission. <i>Best Practice and Research in Clinical Haematology</i> , 2007 , 20, 67-75	4.2	13
371	Graft-versus-host disease: a surge of developments. <i>PLoS Medicine</i> , 2007 , 4, e198	11.6	18
370	Phase II evaluation of an intensified induction therapy with standard daunomycin and cytarabine followed by high dose cytarabine for adults with previously untreated acute myeloid leukemia: a Southwest Oncology Group study (SWOG-9500). <i>American Journal of Hematology</i> , 2007 , 82, 1056-62	7.1	18
369	Hematopoietic-cell transplantation at 50. <i>New England Journal of Medicine</i> , 2007 , 357, 1472-5	59.2	319
368	High-dose [131I]tositumomab (anti-CD20) radioimmunotherapy and autologous hematopoietic stem-cell transplantation for adults > or = 60 years old with relapsed or refractory B-cell lymphoma. <i>Journal of Clinical Oncology</i> , 2007 , 25, 1396-402	2.2	105
367	Benchmarks in clinical productivity: a national comprehensive cancer network survey. <i>Journal of Oncology Practice</i> , 2007 , 3, 2-8	3.1	11
366	Phase III trial of fludarabine plus cyclophosphamide compared with fludarabine for patients with previously untreated chronic lymphocytic leukemia: US Intergroup Trial E2997. <i>Journal of Clinical Oncology</i> , 2007 , 25, 793-8	2.2	340
365	Prophylactic administration of imatinib after hematopoietic cell transplantation for high-risk Philadelphia chromosome-positive leukemia. <i>Blood</i> , 2007 , 109, 2791-3	2.2	187
364	The effects of imatinib mesylate treatment before allogeneic transplantation for chronic myeloid leukemia. <i>Blood</i> , 2007 , 109, 1782-9	2.2	108
363	End points to establish the efficacy of new agents in the treatment of acute leukemia. <i>Blood</i> , 2007 , 109, 1810-6	2.2	74
362	Blockade of adaptive defensive changes in cholesterol uptake and synthesis in AML by the addition of pravastatin to idarubicin + high-dose Ara-C: a phase 1 study. <i>Blood</i> , 2007 , 109, 2999-3006	2.2	86
361	CD33 expression and P-glycoprotein-mediated drug efflux inversely correlate and predict clinical outcome in patients with acute myeloid leukemia treated with gemtuzumab ozogamicin monotherapy. <i>Blood</i> , 2007 , 109, 4168-70	2.2	150
360	Karyng about karyotyping in adult ALL. <i>Blood</i> , 2007 , 109, 3127-3127	2.2	
359	Hematopoietic cell transplantation specific comorbidity index as an outcome predictor for patients with acute myeloid leukemia in first remission: combined FHCRC and MDACC experiences. <i>Blood</i> , 2007 , 110, 4606-13	2.2	262
358	Marrow fibrosis as a risk factor for posttransplantation outcome in patients with advanced myelodysplastic syndrome or acute myeloid leukemia with multilineage dysplasia. <i>Biology of Blood and Marrow Transplantation</i> , 2007 , 13, 345-54	4.7	40
357	Hematopoietic cell transplantation as curative therapy for idiopathic myelofibrosis, advanced polycythemia vera, and essential thrombocythemia. <i>Biology of Blood and Marrow Transplantation</i> , 2007 , 13, 355-65	4.7	155

356	Nelarabine induces complete remissions in adults with relapsed or refractory T-lineage acute lymphoblastic leukemia or lymphoblastic lymphoma: Cancer and Leukemia Group B study 19801. <i>Blood</i> , 2007 , 109, 5136-42	2.2	226
355	Comprehensive assessment of genetic and molecular features predicting outcome in patients with chronic lymphocytic leukemia: results from the US Intergroup Phase III Trial E2997. <i>Journal of Clinical Oncology</i> , 2007 , 25, 799-804	2.2	296
354	Marqibo (Vincristine Sulfate Liposomes Injection, OPTISOME) Concentrates Vincristine in Tumor Tissue and Lymphoid Malignancy Oriented Tissues in Tumor-Bearing Mice.. <i>Blood</i> , 2007 , 110, 1403-1403	2.2	1
353	Outcome of Hematopoietic Cell Transplant from HLA-Matched Siblings Compared to a Volunteer Unrelated Donors Matched for HLA-A, B, C, DRB1, and DQB1 Alleles.. <i>Blood</i> , 2007 , 110, 170-170	2.2	0
352	Outcome Following Hematopoietic Cell Transplantation for Patients with AML-CR1: Comparison between Matched-Sibling and Unrelated Allografts.. <i>Blood</i> , 2007 , 110, 330-330	2.2	2
351	Phase II Studies of Different Schedules and Doses of the Farnesyl Transferase Inhibitor Tipifarnib (R115777, Zarnestra, NSC-702818) for Patients of Age 70 or Older with Previously Untreated Acute Myeloid Leukemia (AML): A North American Intergroup Study (S0432).. <i>Blood</i> , 2007 , 110, 440-440	2.2	3
350	Higher Doses of Transplanted T and B Cells Are Associated with Greater Incidence of Extensive Chronic GVHD after PBSC Transplantation from HLA-Identical Sibling Donors.. <i>Blood</i> , 2007 , 110, 1077-1077	2.2	2
349	Long-Term Outcome of Autologous Followed by Nonmyeloablative Allografting from HLA-Identical Sibling for Multiple Myeloma (MM).. <i>Blood</i> , 2007 , 110, 3029-3029	2.2	1
348	Inhibition of $\alpha 4 \beta 1$ Integrin Disrupts Adhesion and Enhances Chemotherapy Effect in Multiple Myeloma Cells.. <i>Blood</i> , 2007 , 110, 4805-4805	2.2	
347	Hematopoietic cell transplantation in first complete remission versus early relapse. <i>Best Practice and Research in Clinical Haematology</i> , 2006 , 19, 333-9	4.2	19
346	Reduced incidence of acute and chronic graft-versus-host disease with the addition of thymoglobulin to a targeted busulfan/cyclophosphamide regimen. <i>Biology of Blood and Marrow Transplantation</i> , 2006 , 12, 573-84	4.7	75
345	Improving the efficacy of reduced intensity allogeneic transplantation for lymphoma using radioimmunotherapy. <i>Biology of Blood and Marrow Transplantation</i> , 2006 , 12, 697-702	4.7	34
344	131I-anti-CD45 antibody plus busulfan and cyclophosphamide before allogeneic hematopoietic cell transplantation for treatment of acute myeloid leukemia in first remission. <i>Blood</i> , 2006 , 107, 2184-91	2.2	132
343	Age and acute myeloid leukemia. <i>Blood</i> , 2006 , 107, 3481-5	2.2	941
342	The clinical spectrum of adult acute myeloid leukaemia associated with core binding factor translocations. <i>British Journal of Haematology</i> , 2006 , 135, 165-73	4.5	196
341	Relationship between CD33 Expression, P-Glycoprotein-Mediated Drug Efflux, and Clinical Outcome in Patients Treated in Phase II Trials with Gemtuzumab Ozogamicin Monotherapy.. <i>Blood</i> , 2006 , 108, 2324-2324	2.2	1
340	Frequent PML-RAR Δ Mutations in Relapse Patients on Acute Promyelocytic Leukemia (APL) Intergroup Phase III Trial C9710.. <i>Blood</i> , 2006 , 108, 2342-2342	2.2	1
339	A Phase II Trial of 90Y-Ibritumomab Tiuxetan-Based Reduced Intensity Allogeneic Peripheral Blood Stem Cell (PBSC) Transplantation for Relapsed CD20+ B-Cell Non-Hodgkins Lymphoma (NHL).. <i>Blood</i> , 2006 , 108, 316-316	2.2	10

338	Minimal Residual Disease (MRD) and Risk of Relapse in Acute Promyelocytic Leukemia (APL): Insights from the North American Intergroup Phase III Trial C9710.. <i>Blood</i> , 2006 , 108, 494-494	2.2	2
337	Preliminary Results from the North American Acute Promyelocytic Leukemia (APL) Study C9710.. <i>Blood</i> , 2006 , 108, 566-566	2.2	5
336	Conventional and Pretargeted Radioimmunotherapy Using an Anti-Murine CD45 Monoclonal Antibody in a Syngeneic, Disseminated Murine Leukemia Model.. <i>Blood</i> , 2006 , 108, 570-570	2.2	2
335	Changes in the Pattern of Cytogenetic Aberrations with Advancing Age in Acute Myeloid (Non-APL) Leukemia: A Southwest Oncology Study (S9007).. <i>Blood</i> , 2006 , 108, 808-808	2.2	
334	Lack of Utility of Chimerism Studies at Day 80 after Myeloablative Hematopoietic Cell Transplantation for Acute Lymphocytic Leukemia.. <i>Blood</i> , 2006 , 108, 2959-2959	2.2	
333	A phase II multicenter study of visilizumab, humanized anti-CD3 antibody, to treat steroid-refractory acute graft-versus-host disease. <i>Biology of Blood and Marrow Transplantation</i> , 2005 , 11, 465-71	4.7	71
332	Innovations in preparative regimens for autologous hematopoietic cell transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2005 , 11, 40-2	4.7	
331	A phase I/II study of mycophenolate mofetil in combination with cyclosporine for prophylaxis of acute graft-versus-host disease after myeloablative conditioning and allogeneic hematopoietic cell transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2005 , 11, 495-505	4.7	108
330	Allogeneic hematopoietic cell transplantation for chronic myelomonocytic leukemia. <i>Biology of Blood and Marrow Transplantation</i> , 2005 , 11, 713-20	4.7	51
329	Addition of rituximab to fludarabine may prolong progression-free survival and overall survival in patients with previously untreated chronic lymphocytic leukemia: an updated retrospective comparative analysis of CALGB 9712 and CALGB 9011. <i>Blood</i> , 2005 , 105, 49-53	2.2	349
328	Final adult height of patients who received hematopoietic cell transplantation in childhood. <i>Blood</i> , 2005 , 105, 1348-54	2.2	92
327	Allogeneic hematopoietic cell transplantation for infants with acute lymphoblastic leukemia. <i>Blood</i> , 2005 , 105, 3749-56	2.2	69
326	Increased AF1q gene expression in high-risk myelodysplastic syndrome. <i>British Journal of Haematology</i> , 2005 , 128, 218-20	4.5	23
325	Final report of the efficacy and safety of gemtuzumab ozogamicin (Mylotarg) in patients with CD33-positive acute myeloid leukemia in first recurrence. <i>Cancer</i> , 2005 , 104, 1442-52	6.4	364
324	Ablative allogeneic hematopoietic cell transplantation in adults 60 years of age and older. <i>Journal of Clinical Oncology</i> , 2005 , 23, 3439-46	2.2	96
323	131I-Anti-CD45 Antibody Plus Fludarabine, Low-Dose Total Body Irradiation and Peripheral Blood Stem Cell Infusion for Elderly Patients with Advanced Acute Myeloid Leukemia (AML) or High-Risk Myelodysplastic Syndrome (MDS).. <i>Blood</i> , 2005 , 106, 397-397	2.2	18
322	A Phase II Study of Myeloablative I-131-Anti CD-20 (Tositumomab) Radioimmunotherapy and Autologous Hematopoietic Stem Cell Transplantation (ASCT) for Adults ≥0 Years of Age with High-Risk Relapsed or Refractory B-Cell Lymphoma.. <i>Blood</i> , 2005 , 106, 487-487	2.2	4
321	Very Poor Survival of Patients with AML Who Relapse after Achieving a First Complete Remission: The Eastern Cooperative Oncology Group Experience.. <i>Blood</i> , 2005 , 106, 546-546	2.2	18

320	Very Late Antigen-4 (VLA-4) Expression by AML Blasts: Correlation of VCAM-1 Binding to Overall Survival.. <i>Blood</i> , 2005 , 106, 2365-2365	2.2	
319	Blockade of Adaptive Defensive Changes in Cholesterol Uptake and Synthesis in AML by the Addition of Pravastatin to Idarubicin + High Dose Ara-C: A Phase I Study.. <i>Blood</i> , 2005 , 106, 405-405	2.2	1
318	Phase III Trial of All-Trans Retinoic Acid (ATRA) vs Daunorubicin (D) and Cytosine Arabinoside (A) as Induction Therapy and ATRA vs Observation as Maintenance Therapy for Children with Newly Diagnosed Acute Promyelocytic Leukemia (APL).. <i>Blood</i> , 2005 , 106, 894-894	2.2	
317	Biodistribution of yttrium-90-labeled anti-CD45 antibody in a nonhuman primate model. <i>Clinical Cancer Research</i> , 2005 , 11, 787-94	12.9	8
316	Targeted busulfan and cyclophosphamide as compared to busulfan and TBI as preparative regimens for transplantation in patients with advanced MDS or transformation to AML. <i>Leukemia and Lymphoma</i> , 2004 , 45, 2409-17	1.9	25
315	Hematologic responses of patients with MDS to antithymocyte globulin plus etanercept correlate with improved flow scores of marrow cells. <i>Leukemia Research</i> , 2004 , 28, 1177-80	2.7	40
314	Immunobiologic therapies for myelodysplastic syndrome. <i>Best Practice and Research in Clinical Haematology</i> , 2004 , 17, 653-61	4.2	3
313	Increasingly frequent diagnosis of acute gastrointestinal graft-versus-host disease after allogeneic hematopoietic cell transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2004 , 10, 320-7	4.7	126
312	Evaluation of a CD25-specific immunotoxin for prevention of graft-versus-host disease after unrelated marrow transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2004 , 10, 552-60	4.7	55
311	The peripheral benzodiazepine receptor ligand PK11195 overcomes different resistance mechanisms to sensitize AML cells to gemtuzumab ozogamicin. <i>Blood</i> , 2004 , 103, 4276-84	2.2	76
310	Female donors contribute to a selective graft-versus-leukemia effect in male recipients of HLA-matched, related hematopoietic stem cell transplants. <i>Blood</i> , 2004 , 103, 347-52	2.2	202
309	Microgranular Variant (M3V) of Acute Promyelocytic Leukemia (APL) Does Not Have a Worse Prognosis than Classical APL in the ATRA Era: A Report of 153 Patients Treated on Intergroup 0129 and Pethema LPA96 and LPA99.. <i>Blood</i> , 2004 , 104, 394-394	2.2	4
308	131I-Anti-CD45 Antibody Plus Busulfan/Cyclophosphamide in Matched Related Transplants for Acute Myeloid Leukemia in First Remission.. <i>Blood</i> , 2004 , 104, 813-813	2.2	2
307	A Myeloablative Regimen Incorporating Radiolabeled Anti-CD45 (BC8) Antibody Followed by Allogeneic Hematopoietic Cell Transplantation (HCT) for Patients with Advanced Acute Myeloid Leukemia (AML).. <i>Blood</i> , 2004 , 104, 828-828	2.2	2
306	Acute Myeloid Leukemia (AML) with t(6;9)(p23;q34) Defines a Very Poor Risk Leukemia Subgroup with Distinguishing Clinicopathological Features: A United States (US) Cytogenetics Intergroup Study of 62 AML and MDS Cases.. <i>Blood</i> , 2004 , 104, 567-567	2.2	1
305	Allogeneic hematopoietic stem cell transplantation for myelofibrosis. <i>Blood</i> , 2003 , 102, 3912-8	2.2	228
304	Cholesterol-modulating agents kill acute myeloid leukemia cells and sensitize them to therapeutics by blocking adaptive cholesterol responses. <i>Blood</i> , 2003 , 101, 3628-34	2.2	153
303	Allografting with nonmyeloablative conditioning following cytoreductive autografts for the treatment of patients with multiple myeloma. <i>Blood</i> , 2003 , 102, 3447-54	2.2	346

302	Conditioning with fludarabine and targeted busulfan for transplantation of allogeneic hematopoietic stem cells. <i>Blood</i> , 2003 , 102, 820-6	2.2	172
301	High-dose radioimmunotherapy versus conventional high-dose therapy and autologous hematopoietic stem cell transplantation for relapsed follicular non-Hodgkin lymphoma: a multivariable cohort analysis. <i>Blood</i> , 2003 , 102, 2351-7	2.2	172
300	HLA-matched related hematopoietic cell transplantation for chronic-phase CML using a targeted busulfan and cyclophosphamide preparative regimen. <i>Blood</i> , 2003 , 102, 31-5	2.2	150
299	Non-myeloablative allografting from human leucocyte antigen-identical sibling donors for treatment of acute myeloid leukaemia in first complete remission. <i>British Journal of Haematology</i> , 2003 , 120, 281-8	4.5	80
298	Prognostic significance of CD38 and CD20 expression as assessed by quantitative flow cytometry in chronic lymphocytic leukaemia. <i>British Journal of Haematology</i> , 2003 , 120, 1017-25	4.5	38
297	Predictive factors for outcome of allogeneic hematopoietic cell transplantation for adult acute lymphoblastic leukemia. <i>Biology of Blood and Marrow Transplantation</i> , 2003 , 9, 472-81	4.7	68
296	Quantitative real-time RT-PCR analysis of PML-RAR alpha mRNA in acute promyelocytic leukemia: assessment of prognostic significance in adult patients from intergroup protocol 0129. <i>Blood</i> , 2003 , 101, 2521-8	2.2	124
295	The current status of hematopoietic cell transplantation. <i>Annual Review of Medicine</i> , 2003 , 54, 491-512	17.4	109
294	Predictors of relapse and overall survival in Philadelphia chromosome-positive acute lymphoblastic leukemia after transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2003 , 9, 206-12	4.7	57
293	Therapy-related myeloid leukemias are observed in patients with chronic lymphocytic leukemia after treatment with fludarabine and chlorambucil: results of an intergroup study, cancer and leukemia group B 9011. <i>Journal of Clinical Oncology</i> , 2002 , 20, 3878-84	2.2	143
292	Hematopoietic cell transplantation as a form of immunotherapy. <i>International Journal of Hematology</i> , 2002 , 75, 222-7	2.3	8
291	PK11195, a peripheral benzodiazepine receptor ligand, chemosensitizes acute myeloid leukemia cells to relevant therapeutic agents by more than one mechanism. <i>Leukemia Research</i> , 2002 , 26, 91-106	2.7	42
290	Conditioning with targeted busulfan and cyclophosphamide for hemopoietic stem cell transplantation from related and unrelated donors in patients with myelodysplastic syndrome. <i>Blood</i> , 2002 , 100, 1201-7	2.2	253
289	Factors associated with outcome after unrelated marrow transplantation for treatment of acute lymphoblastic leukemia in children. <i>Blood</i> , 2002 , 99, 2002-8	2.2	106
288	High-dose chemo-radioimmunotherapy with autologous stem cell support for relapsed mantle cell lymphoma. <i>Blood</i> , 2002 , 99, 3158-62	2.2	187
287	Therapy for chronic graft-versus-host disease: a randomized trial comparing cyclosporine plus prednisone versus prednisone alone. <i>Blood</i> , 2002 , 100, 48-51	2.2	227
286	A humanized non-FcR-binding anti-CD3 antibody, visilizumab, for treatment of steroid-refractory acute graft-versus-host disease. <i>Blood</i> , 2002 , 99, 2712-9	2.2	143
285	Outcome after induction chemotherapy for older patients with acute myeloid leukemia is not improved with mitoxantrone and etoposide compared to cytarabine and daunorubicin: a Southwest Oncology Group study. <i>Blood</i> , 2002 , 100, 3869-76	2.2	153

284	All-trans retinoic acid in acute promyelocytic leukemia: long-term outcome and prognostic factor analysis from the North American Intergroup protocol. <i>Blood</i> , 2002 , 100, 4298-302	2.2	379
283	Impact of trisomy 8 (+8) on clinical presentation, treatment response, and survival in acute myeloid leukemia: a Southwest Oncology Group study. <i>Blood</i> , 2002 , 100, 29-35	2.2	66
282	Psoralen and ultraviolet A irradiation (PUVA) as therapy for steroid-resistant cutaneous acute graft-versus-host disease. <i>Biology of Blood and Marrow Transplantation</i> , 2002 , 8, 206-12	4.7	59
281	Comparison of chronic graft-versus-host disease after transplantation of peripheral blood stem cells versus bone marrow in allogeneic recipients: long-term follow-up of a randomized trial. <i>Blood</i> , 2002 , 100, 415-9	2.2	358
280	Curative therapy of advanced essential thrombocythemia or polycythemia vera by hemopoietic stem cell transplantation. <i>Leukemia and Lymphoma</i> , 2002 , 43, 1409-14	1.9	16
279	Hematopoietic stem cell transplantation for advanced myelodysplastic syndrome after conditioning with busulfan and fractionated total body irradiation is associated with low relapse rate but considerable nonrelapse mortality. <i>Biology of Blood and Marrow Transplantation</i> , 2002 , 8, 161-9	4.7	55
278	Cyclosporine inhibition of P-glycoprotein in chronic myeloid leukemia blast phase. <i>Blood</i> , 2002 , 100, 1910-2	2.2	18
277	Multidrug-resistance phenotype and clinical responses to gemtuzumab ozogamicin. <i>Blood</i> , 2001 , 98, 988-94	2.2	176
276	Immune reconstitution after allogeneic marrow transplantation compared with blood stem cell transplantation. <i>Blood</i> , 2001 , 97, 3380-9	2.2	312
275	Splenectomy and hemopoietic stem cell transplantation for myelofibrosis. <i>Blood</i> , 2001 , 97, 2180-1	2.2	58
274	Experiences of donors enrolled in a randomized study of allogeneic bone marrow or peripheral blood stem cell transplantation. <i>Blood</i> , 2001 , 97, 2541-8	2.2	81
273	Benefit of cyclosporine modulation of drug resistance in patients with poor-risk acute myeloid leukemia: a Southwest Oncology Group study. <i>Blood</i> , 2001 , 98, 3212-20	2.2	352
272	Immunity of patients surviving 20 to 30 years after allogeneic or syngeneic bone marrow transplantation. <i>Blood</i> , 2001 , 98, 3505-12	2.2	107
271	Administration of cyclosporine for 24 months compared with 6 months for prevention of chronic graft-versus-host disease: a prospective randomized clinical trial. <i>Blood</i> , 2001 , 98, 3868-70	2.2	57
270	Myeloablation and autologous peripheral blood stem cell rescue results in hematologic and clinical responses in patients with myeloid metaplasia with myelofibrosis. <i>Blood</i> , 2001 , 98, 586-93	2.2	66
269	The significance of bcr-abl molecular detection in chronic myeloid leukemia patients "late," 18 months or more after transplantation. <i>Blood</i> , 2001 , 98, 1701-7	2.2	120
268	FLT3, RAS, and TP53 mutations in elderly patients with acute myeloid leukemia. <i>Blood</i> , 2001 , 97, 3589-95	2.2	361
267	Haematopoietic cell transplantation as immunotherapy. <i>Nature</i> , 2001 , 411, 385-9	50.4	341

266	Blasts from elderly acute myeloid leukemia patients are characterized by low levels of culture- and drug-induced apoptosis. <i>Leukemia Research</i> , 2001 , 25, 23-32	2.7	20
265	Acute myeloid leukemia cells are protected from spontaneous and drug-induced apoptosis by direct contact with a human bone marrow stromal cell line (HS-5). <i>Experimental Hematology</i> , 2001 , 29, 448-57	3.1	173
264	Economic analysis of granulocyte colony stimulating factor as adjunct therapy for older patients with acute myelogenous leukemia (AML): estimates from a Southwest Oncology Group clinical trial. <i>Cancer Investigation</i> , 2001 , 19, 603-10	2.1	34
263	Stem-cell transplantation for myelofibrosis. <i>New England Journal of Medicine</i> , 2001 , 344, 775-6	59.2	12
262	Cyclophosphamide and antithymocyte globulin to condition patients with aplastic anemia for allogeneic marrow transplantations: the experience in four centers. <i>Biology of Blood and Marrow Transplantation</i> , 2001 , 7, 39-44	4.7	131
261	Relapse after allogeneic bone marrow transplantation for refractory anemia is increased by shielding lungs and liver during total body irradiation. <i>Biology of Blood and Marrow Transplantation</i> , 2001 , 7, 163-70	4.7	20
260	Hematopoietic cell transplantation in older patients with hematologic malignancies: replacing high-dose cytotoxic therapy with graft-versus-tumor effects. <i>Blood</i> , 2001 , 97, 3390-400	2.2	1183
259	Transplantation of bone marrow as compared with peripheral-blood cells from HLA-identical relatives in patients with hematologic cancers. <i>New England Journal of Medicine</i> , 2001 , 344, 175-81	59.2	831
258	Hematopoietic stem-cell transplantation for treatment-related leukemia or myelodysplasia. <i>Journal of Clinical Oncology</i> , 2001 , 19, 2134-41	2.2	72
257	Impact of therapy With chlorambucil, fludarabine, or fludarabine plus chlorambucil on infections in patients with chronic lymphocytic leukemia: Intergroup Study Cancer and Leukemia Group B 9011. <i>Journal of Clinical Oncology</i> , 2001 , 19, 3611-21	2.2	121
256	Efficacy and safety of gemtuzumab ozogamicin in patients with CD33-positive acute myeloid leukemia in first relapse. <i>Journal of Clinical Oncology</i> , 2001 , 19, 3244-54	2.2	733
255	Sirolimus (rapamycin) for the treatment of steroid-refractory acute graft-versus-host disease. <i>Transplantation</i> , 2001 , 72, 1924-9	1.8	152
254	Hemopoietic stem cell transplantation for myelodysplastic syndrome. <i>Current Opinion in Oncology</i> , 2000 , 12, 116-20	4.2	10
253	Three-color versus four-color multiparameter cell cycle analyses of primary acute myeloid leukemia samples. <i>Cytometry</i> , 2000 , 42, 83-94		11
252	Twenty-four-color spectral karyotyping reveals chromosome aberrations in cytogenetically normal acute myeloid leukemia. <i>Genes Chromosomes and Cancer</i> , 2000 , 28, 318-28	5	47
251	Allogeneic stem cell transplantation for relapsed and refractory acute myeloid leukemia patients with 11q23 abnormalities. <i>Leukemia Research</i> , 2000 , 24, 481-6	2.7	13
250	A phase I study of induction chemotherapy for older patients with newly diagnosed acute myeloid leukemia (AML) using mitoxantrone, etoposide, and the MDR modulator PSC 833: a southwest oncology group study 9617. <i>Leukemia Research</i> , 2000 , 24, 567-74	2.7	56
249	Hematopoietic stem cell transplantation in patients with myelodysplastic syndrome. <i>Leukemia Research</i> , 2000 , 24, 653-63	2.7	31

248	A phase II study of high dose ARA-C and mitoxantrone for treatment of relapsed or refractory adult acute lymphoblastic leukemia. <i>Leukemia Research</i> , 2000 , 24, 183-7	2.7	20
247	Thalidomide for treatment of patients with chronic graft-versus-host disease. <i>Blood</i> , 2000 , 96, 3995-3996.2		108
246	Fludarabine compared with chlorambucil as primary therapy for chronic lymphocytic leukemia. <i>New England Journal of Medicine</i> , 2000 , 343, 1750-7	59.2	840
245	Second allogeneic transplantation after failure of first autologous transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2000 , 6, 272-9	4.7	83
244	A phase I trial of recombinant human thrombopoietin in patients with delayed platelet recovery after hematopoietic stem cell transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2000 , 6, 25-34	4.7	65
243	Granulocyte colony-stimulating factor given to donors before apheresis does not prevent aplasia in patients treated with donor leukocyte infusion for recurrent chronic myeloid leukemia after bone marrow transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2000 , 6, 321-6	4.7	29
242	A phase I/II trial of iodine-131Eositimomab (anti-CD20), etoposide, cyclophosphamide, and autologous stem cell transplantation for relapsed B-cell lymphomas. <i>Blood</i> , 2000 , 96, 2934-2942	2.2	6
241	Phase I Study of 131I-Anti-CD45 Antibody Plus Cyclophosphamide and Total Body Irradiation for Advanced Acute Leukemia and Myelodysplastic Syndrome. <i>Blood</i> , 1999 , 94, 1237-1247	2.2	253
240	A phase III comparison of high dose ARA-C (HIDAC) versus HIDAC plus mitoxantrone in the treatment of first relapsed or refractory acute myeloid leukemia Southwest Oncology Group Study. <i>Leukemia Research</i> , 1999 , 23, 787-94	2.7	65
239	Dose rate-dependent marrow toxicity of TBI in dogs and marrow sparing effect at high dose rate by dose fractionation. <i>Biology of Blood and Marrow Transplantation</i> , 1999 , 5, 155-61	4.7	14
238	Pharmacokinetics of cyclophosphamide and its metabolites in bone marrow transplantation patients. <i>Clinical Pharmacology and Therapeutics</i> , 1998 , 64, 289-301	6.1	59
237	Cell cycle perturbations in acute myeloid leukemia samples following in vitro exposures to therapeutic agents. <i>Leukemia Research</i> , 1998 , 22, 221-39	2.7	36
236	Bone marrow transplants from unrelated donors for patients with chronic myeloid leukemia. <i>New England Journal of Medicine</i> , 1998 , 338, 962-8	59.2	541
235	Chemotherapy compared with autologous or allogeneic bone marrow transplantation in the management of acute myeloid leukemia in first remission. <i>New England Journal of Medicine</i> , 1998 , 339, 1649-56	59.2	506
234	Myelodysplasia and myeloproliferative disorders. <i>Current Opinion in Hematology</i> , 1997 , 4, 261-7	3.3	4
233	All-trans-retinoic acid in acute promyelocytic leukemia. <i>New England Journal of Medicine</i> , 1997 , 337, 1021-8.2	59.2	895
232	Transplantation of Marrow Cells From Unrelated Donors for Treatment of High-Risk Acute Leukemia: The Effect of Leukemic Burden, Donor HLA-Matching, and Marrow Cell Dose. <i>Blood</i> , 1997 , 89, 4226-4235	2.2	334
231	Allogeneic marrow transplantation for primary myelofibrosis and myelofibrosis secondary to polycythaemia vera or essential thrombocytosis. <i>British Journal of Haematology</i> , 1997 , 98, 1010-6	4.5	60

230	Long-term survival after chemotherapy for acute myeloid leukemia. <i>Cancer</i> , 1997 , 80, 2199-2204	6.4	38
229	Cyclosporine or Cyclosporine Plus Methylprednisolone for Prophylaxis of Graft-Versus-Host Disease: A Prospective, Randomized Trial. <i>Blood</i> , 1997 , 89, 3880-3887	2.2	3
228	Long-term survival after chemotherapy for acute myeloid leukemia: the experience of the Southwest Oncology Group. <i>Cancer</i> , 1997 , 80, 2199-204	6.4	9
227	The role of radioimmunotherapy in bone marrow transplantation. <i>Current Opinion in Hematology</i> , 1996 , 3, 438-45	3.3	8
226	The use of bone marrow and peripheral blood stem cell transplantation in the treatment of cancer. <i>Ca-A Cancer Journal for Clinicians</i> , 1996 , 46, 142-64	220.7	51
225	Marrow transplantation for Fanconi anaemia: conditioning with reduced doses of cyclophosphamide without radiation. <i>British Journal of Haematology</i> , 1996 , 92, 699-706	4.5	40
224	Unrelated donor marrow transplantation for myelodysplasia (MDS) and MDS-related acute myeloid leukaemia. <i>British Journal of Haematology</i> , 1996 , 93, 59-67	4.5	100
223	The problem of thrombocytopenia after hematopoietic stem cell transplantation. <i>Stem Cells</i> , 1996 , 14 Suppl 1, 261-73	5.8	36
222	The Problem of Thrombocytopenia after Hematopoietic Stem Cell Transplantation. <i>Oncologist</i> , 1996 , 1, 371-380	5.7	28
221	Cytogenetic correlation with disease status and treatment outcome in advanced stage leukemia post bone marrow transplantation: a Southwest Oncology Group study (SWOG-8612). <i>Leukemia Research</i> , 1995 , 19, 381-8	2.7	25
220	Effects of vitamin A on survival in patients with chronic myelogenous leukemia: a SWOG randomized trial. <i>Leukemia Research</i> , 1995 , 19, 605-12	2.7	22
219	Allogeneic marrow transplantation and the use of hematopoietic growth factors. <i>Stem Cells</i> , 1995 , 13, 344-50	5.8	19
218	An update on allogeneic marrow transplantation for myelodysplastic syndrome. <i>Leukemia and Lymphoma</i> , 1995 , 17, 95-9	1.9	34
217	Trisomy 11: an association with stem/progenitor cell immunophenotype. <i>British Journal of Haematology</i> , 1995 , 90, 266-73	4.5	30
216	Treatment of acute myelogenous leukemia in patients over 50 years of age with V-TAD: a Southwest Oncology Group study. <i>American Journal of Hematology</i> , 1995 , 48, 228-32	7.1	2
215	Allogeneic marrow transplantation following cyclophosphamide and escalating doses of hyperfractionated total body irradiation in patients with advanced lymphoid malignancies: a Phase I/II trial. <i>International Journal of Radiation Oncology Biology Physics</i> , 1995 , 32, 1103-9	4	32
214	Availability and appropriateness of allogeneic bone marrow transplantation for chronic myeloid leukemia in 10 countries. <i>New England Journal of Medicine</i> , 1994 , 331, 1063-7	59.2	46
213	Post therapy imaging in high dose I-131 radioimmunotherapy patients. <i>Medical Physics</i> , 1994 , 21, 1157-62.4	62.4	12

212	Failure of a single cycle of high dose cyclophosphamide followed by intensive myeloablative therapy and autologous stem cell transplantation to improve outcome in relapsed disease. <i>Cancer</i> , 1994 , 74, 715-21	6.4	5
211	Autologous bone marrow transplantation in adults with non-Hodgkin's lymphoma: a Southwest Oncology Group study. <i>Hematological Oncology</i> , 1994 , 12, 75-85	1.3	9
210	Gamma-irradiation of pretransplant blood transfusions from unrelated donors prevents sensitization to minor histocompatibility antigens on dog leukocyte antigen-identical canine marrow grafts. <i>Transplantation</i> , 1994 , 57, 423-6	1.8	27
209	Radiolabeled-antibody therapy of B-cell lymphoma with autologous bone marrow support. <i>New England Journal of Medicine</i> , 1993 , 329, 1219-24	59.2	525
208	Studies of the use of L-leucyl-L-leucine methyl ester in canine allogeneic marrow transplantation. <i>Transplantation</i> , 1993 , 55, 1244-9	1.8	6
207	FK-506 and methotrexate prevent graft-versus-host disease in dogs given 9.2 Gy total body irradiation and marrow grafts from unrelated dog leukocyte antigen-nonidentical donors. <i>Transplantation</i> , 1993 , 56, 800-7	1.8	37
206	The use of colony stimulating factors in marrow transplantation. <i>Cancer</i> , 1993 , 72, 3387-92	6.4	10
205	Recombinant granulocyte-macrophage colony stimulating factor followed by immunosuppressive therapy for aplastic anaemia. <i>British Journal of Haematology</i> , 1993 , 85, 182-4	4.5	8
204	The use of radiolabeled anti-CD33 antibody to augment marrow irradiation prior to marrow transplantation for acute myelogenous leukemia. <i>Transplantation</i> , 1992 , 54, 829-33	1.8	136
203	Treatment of acute graft-versus-host disease with a nonmitogenic anti-CD3 monoclonal antibody. <i>Transplantation</i> , 1992 , 54, 844-51	1.8	44
202	Succinyl acetone plus methotrexate as graft-versus-host disease prophylaxis in DLA-haploidentical canine littermate marrow grafts. <i>Transplantation</i> , 1992 , 54, 947-8	1.8	3
201	A pilot study of low-dose cyclosporin for graft-versus-host prophylaxis in marrow transplantation. <i>British Journal of Haematology</i> , 1992 , 80, 49-54	4.5	28
200	Recombinant granulocyte-macrophage colony-stimulating factor after autologous bone marrow transplantation for lymphoid cancer. <i>New England Journal of Medicine</i> , 1991 , 324, 1773-8	59.2	400
199	Bone marrow transplantation in canine GM1 gangliosidosis. <i>Clinical Genetics</i> , 1990 , 38, 274-80	4	22
198	The somatostatin analog octreotide in the management of the secretory diarrhea of the acute intestinal graft-versus-host disease in a patient after bone marrow transplantation. <i>Transplantation</i> , 1990 , 49, 1194-5	1.8	25
197	Biotherapy after marrow transplantation and the use of hematopoietic growth factors. <i>Current Opinion in Oncology</i> , 1990 , 2, 289-96	4.2	2
196	A phase I-II study evaluating the murine anti-IL-2 receptor antibody 2A3 for treatment of acute graft-versus-host disease. <i>Transplantation</i> , 1990 , 50, 49-54	1.8	45
195	Inadvertent transmission of a donor's acute myeloid leukemia in bone marrow transplantation for chronic myelocytic leukemia. <i>New England Journal of Medicine</i> , 1990 , 322, 1794-6	59.2	84

194	Immunomodulatory and antimicrobial efficacy of intravenous immunoglobulin in bone marrow transplantation. <i>New England Journal of Medicine</i> , 1990 , 323, 705-12	59.2	326
193	Prevalence of clinically relevant bacteremia after upper gastrointestinal endoscopy in bone marrow transplant recipients. <i>American Journal of Medicine</i> , 1990 , 89, 134-6	2.4	36
192	Bone marrow transplantation for patients with myelodysplasia. Pretreatment variables and outcome. <i>Annals of Internal Medicine</i> , 1990 , 112, 590-7	8	100
191	Graft-versus-host disease as adoptive immunotherapy in patients with advanced hematologic neoplasms. <i>New England Journal of Medicine</i> , 1989 , 320, 828-34	59.2	277
190	Graft-versus-host disease prevention by methotrexate combined with cyclosporin compared to methotrexate alone in patients given marrow grafts for severe aplastic anaemia: long-term follow-up of a controlled trial. <i>British Journal of Haematology</i> , 1989 , 72, 567-72	4.5	79
189	Effect of HLA compatibility on engraftment of bone marrow transplants in patients with leukemia or lymphoma. <i>New England Journal of Medicine</i> , 1989 , 320, 197-204	59.2	552
188	Marrow transplantation in the treatment of patients with lymphoma. <i>Current Opinion in Oncology</i> , 1989 , 1, 47-54	4.2	2
187	Failure of anti-Ia monoclonal antibody to abrogate transfusion-induced sensitization and prevent marrow graft rejection in DLA-identical canine littermates. <i>Transplantation</i> , 1988 , 45, 505-6	1.8	5
186	Allogeneic bone marrow transplantation in irradiated adult rabbits. <i>Transplantation</i> , 1987 , 44, 351-4	1.8	2
185	Facilitation of engraftment of DLA-nonidentical marrow by treatment of recipients with monoclonal antibody directed against marrow cells surviving radiation. <i>Transplantation</i> , 1987 , 44, 607-13	1.8	20
184	Engraftment of DLA-nonidentical bone marrow facilitated by recipient treatment with anti-class II monoclonal antibody and methotrexate. <i>Transplantation</i> , 1987 , 44, 340-5	1.8	8
183	Bone marrow transplantation for malignant lymphoma. <i>European Journal of Cancer & Clinical Oncology</i> , 1987 , 23, 263-6		5
182	Does histologic grading of inflammation in bone marrow predict the response of aplastic anaemia patients to antithymocyte globulin therapy?. <i>British Journal of Haematology</i> , 1987 , 67, 261-6	4.5	5
181	VENOCLUSIVE DISEASE OF THE LIVER AFTER CHEMORADIOTHERAPY AND AUTOLOGOUS BONE MARROW TRANSPLANTATION ¹ . <i>Transplantation</i> , 1987 , 43, 870-873	1.8	
180	Cure of malignant lymphoma in dogs with peripheral blood stem cell transplantation. <i>Transplantation</i> , 1986 , 42, 19-22	1.8	31
179	Interstitial pneumonitis following autologous bone marrow transplantation. <i>Transplantation</i> , 1986 , 42, 515-7	1.8	79
178	Cyclic neutropenia as a premalignant manifestation of acute lymphoblastic leukemia. <i>American Journal of Hematology</i> , 1986 , 22, 9-16	7.1	11
177	Selection of patients with Hodgkin's disease and non-Hodgkin's lymphoma for bone marrow transplantation. <i>International Journal of Cell Cloning</i> , 1986 , 4 Suppl 1, 94-106		15

176	Methotrexate and cyclosporine compared with cyclosporine alone for prophylaxis of acute graft versus host disease after marrow transplantation for leukemia. <i>New England Journal of Medicine</i> , 1986 , 314, 729-35	59.2	1113
175	Treatment of human acute graft-versus-host disease with antithymocyte globulin and cyclosporine with or without methylprednisolone. <i>Transplantation</i> , 1985 , 40, 162-6	1.8	52
174	Marrow transplant studies in dogs with malignant lymphoma. <i>Transplantation</i> , 1985 , 39, 499-504	1.8	25
173	Marrow transplantation for leukemia following fractionated total body irradiation. A comparative trial of methotrexate and cyclosporine. <i>Leukemia Research</i> , 1985 , 9, 1255-61	2.7	28
172	Marrow transplant experience in children with acute lymphoblastic leukemia: an analysis of factors associated with survival, relapse, and graft-versus-host disease. <i>Medical and Pediatric Oncology</i> , 1985 , 13, 165-72		54
171	Treatment of acute leukemia in adults with chemoradiotherapy and bone marrow transplantation. <i>Cancer</i> , 1985 , 55, 2202-9	6.4	28
170	Treatment of acute graft-versus-host disease after allogeneic marrow transplantation. Randomized study comparing corticosteroids and cyclosporine. <i>American Journal of Medicine</i> , 1985 , 78, 978-83	2.4	54
169	Allogeneic marrow transplantation in the treatment of preleukemia. <i>Annals of Internal Medicine</i> , 1984 , 100, 689-93	8	71
168	Phenotyping of canine lymphoma with monoclonal antibodies directed at cell surface antigens: classification, morphology, clinical presentation and response to chemotherapy. <i>Hematological Oncology</i> , 1984 , 2, 151-68	1.3	62
167	Combined immunosuppression with cyclosporine and methotrexate in dogs given bone marrow grafts from DLA-haploidentical littermates. <i>Transplantation</i> , 1984 , 37, 62-5	1.8	34
166	Bone marrow transplantation or chemotherapy after remission induction for adults with acute nonlymphoblastic leukemia. A prospective comparison. <i>Annals of Internal Medicine</i> , 1984 , 101, 581-8	8	135
165	Chronic myelogenous leukemia. Prolonged survival with spontaneous decline in the frequency of Ph1-positive cells and subsequent development of mixed Ph1-positive and Ph1-negative blast crisis. <i>Cancer</i> , 1983 , 51, 149-53	6.4	14
164	Treatment of hairy-cell leukemia with chemoradiotherapy and identical-twin bone-marrow transplantation. <i>New England Journal of Medicine</i> , 1982 , 307, 479-81	59.2	52
163	Treatment of chronic granulocytic leukemia with chemoradiotherapy and transplantation of marrow from identical twins. <i>New England Journal of Medicine</i> , 1982 , 306, 63-8	59.2	117
162	Nonbacterial nonfungal pneumonia following marrow transplantation in 100 identical twins. <i>Transplantation</i> , 1982 , 33, 265-8	1.8	80
161	Prolonged complete remission following high dose chemotherapy of Burkitt's lymphoma in relapse. <i>Cancer</i> , 1978 , 41, 1059-63	6.4	132
160	Study of cell dose and storage time on engraftment of cryopreserved autologous bone marrow in a canine model. <i>Transplantation</i> , 1978 , 26, 245-8	1.8	51
159	⁶⁷ Ga radionuclide imaging in Burkitt's lymphoma. <i>Radiology</i> , 1975 , 117, 639-45	20.5	20

158	Radiotherapeutic Principles of Hematopoietic Cell Transplantation333-350	
157	Cord Blood Hematopoietic Cell Transplantation559-576	11
156	Immune Reconstitution Following Hematopoietic Cell Transplantation222-231	1
155	The Pathophysiology of Graft-Versus-Host Disease208-221	2
154	A History of Allogeneic Hematopoietic Cell Transplantation1-7	4
153	Uses and Growth of Hematopoietic Cell Transplantation15-21	12
152	The History of Autologous Hematopoietic Cell Transplantation8-14	4
151	Expansion of Hematopoietic Stem Cells88-101	
150	Molecular Biology of Stem Cell Renewal64-71	
149	Biology of Hematopoietic Stem and Progenitor Cells36-63	1
148	Mechanisms of Tolerance188-207	
147	Mesenchymal Stromal Cells and Hematopoietic Cell Transplantation102-115	
146	Cellular Biology of Hematopoiesis72-87	
145	Hematopoietic Cell Transplantation for Multiple Myeloma845-859	
144	Autologous Graft-vs.-Host Disease405-413	
143	Biology of Hematopoietic Stem and Progenitor Cells69-95	1
142	Graft-vs.-Host Disease633-664	3
141	Nonmyeloablative Therapy and Hematopoietic Cell Transplantation for Hematologic Disorders1164-1176	2

140	Outcomes Research in Hematopoietic Cell Transplantation428-441	1
139	In Utero Transplantation577-589	1
138	Histocompatibility145-162	1
137	Nursing Role in Hematopoietic Cell Transplantation461-477	1
136	Autologous Hematopoietic Cell Transplantation for Non-Hodgkin's Lymphoma1207-1220	1
135	Hematopoietic Cell Transplantation for Storage Diseases1455-1470	2
134	Hematopoietic Cell Transplantation for Immunodeficiency Diseases1430-1442	3
133	Hematopoietic Cell Transplantation for Fanconi Anemia1483-1504	5
132	Clinical Trials of Gene Marking and Gene Therapy Using Hematopoietic Stem Cells118-129	1
131	Preparative Regimens and Modification of Regimen-Related Toxicities158-177	1
130	T-Cell Depletion to Prevent Graft-vs.-Host Disease221-233	3
129	Documentation of Engraftment and Characterization of Chimerism Following Hematopoietic Cell Transplantation234-244	3
128	Antibody Mediated Purging244-253	1
127	Uses and Growth of Hematopoietic Cell Transplantation9-15	9
126	Mechanisms of Tolerance300-323	2
125	The Experimental Basis for Hematopoietic Cell Transplantation for Autoimmune Diseases324-343	1
124	Murine Models for Graft-Vs.-Host Disease344-352	1
123	The Pathophysiology of Graft-Vs.-Host Disease353-368	7

122	Overview of Hematopoietic Cell Transplantation Immunology16-30	1
121	Hematopoietic Cell Donors538-549	1
120	Cord Blood Hematopoietic Cell Transplantation550-564	3
119	Fungal Infections After Hematopoietic Cell Transplantation683-700	1
118	Cytomegalovirus Infection701-726	4
117	Herpes Simplex Virus Infections727-731	1
116	Epstein-Barr Virus Infection749-756	1
115	Gastrointestinal and Hepatic Complications769-810	3
114	Immunological Reconstitution Following Hematopoietic Cell Transplantation853-861	4
113	Growth and Development After Hematopoietic Cell Transplantation929-943	4
112	Delayed Complications After Hematopoietic Cell Transplantation944-961	2
111	Secondary Malignancies After Hematopoietic Cell Transplantation962-977	2
110	Allogeneic Transplantation for Myelodysplastic and Myeloproliferative Disorders1084-1095	1
109	Hematopoietic Cell Transplantation from Unrelated Donors1132-1149	1
108	Autologous Hematopoietic Cell Transplantation for Multiple Myeloma1262-1282	1
107	Hematopoietic Cell Transplantation for Neuroblastoma1333-1344	1
106	Nutrition Support of the Hematopoietic Cell Transplant Recipient1551-1569	2
105	Oral Complications of Hematopoietic Cell Transplantation1589-1607	7

104	Growth and Development after Hematopoietic Cell Transplantation1608-1619	6
103	Delayed Nonmalignant Complications after Hematopoietic Cell Transplantation1620-1637	3
102	Neurologic Complications of Hematopoietic Cell Transplantation1653-1663	2
101	Vaccination of Allogeneic and Autologous Hematopoietic Cell Recipients1664-1670	2
100	Murine Models of Graft-versus-Host Disease and Graft-versus-Tumor Effect176-187	3
99	The Human Graft-versus-Tumor Response and How to Exploit It232-247	1
98	Dendritic Cells in Hematopoietic Cell Transplantation248-263	1
97	Pharmacologic Basis for High-dose Chemotherapy287-315	4
96	High-dose Preparatory Regimens316-332	2
95	Documentation of Engraftment and Characterization of Chimerism Following Hematopoietic Cell Transplantation365-377	1
94	Pathology of Hematopoietic Cell Transplantation390-405	1
93	The Evaluation and Counseling of Candidates for Hematopoietic Cell Transplantation443-460	2
92	Psychosocial Issues in Hematopoietic Cell Transplantation488-501	2
91	Assessment of Quality of Life in Hematopoietic Cell Transplantation Recipients502-514	1
90	Bone Marrow and Peripheral Blood Cell Donors and Donor Registries544-558	4
89	Mobilization of Autologous Peripheral Blood Hematopoietic Cells for Cellular Therapy590-604	3
88	Hematopoietic Cell Transplantation from Human Leukocyte Antigen Partially Matched Related Donors657-674	1
87	Hematopoietic Cell Transplantation from Unrelated Donors675-691	2

86	Hematopoietic Cell Transplantation for Adult Acute Myeloid Leukemia761-774	3
85	Hematopoietic Cell Transplantation for Acute Lymphoblastic Leukemia in Adults791-805	1
84	Hematopoietic Cell Transplantation for Acute Lymphoblastic Leukemia in Children806-826	1
83	Hematopoietic Cell Transplantation for Myelodysplastic Syndrome and Myeloproliferative Disorders827-844	1
82	Hematopoietic Cell Transplantation for Chronic Lymphocytic Leukemia897-913	1
81	Reduced-intensity Conditioning Followed by Hematopoietic Cell Transplantation for Hematologic Malignancies1043-1055	1
80	Hematopoietic Cell Transplantation for Immunodeficiency Diseases1105-1124	1
79	Hematopoietic Cell Transplantation for Storage Diseases1136-1162	3
78	Principles of Transfusion Support Before and After Hematopoietic Cell Transplantation1226-1243	2
77	Vascular Access and Complications1244-1256	1
76	Pharmacologic Prevention of Acute Graft-Versus-Host Disease1257-1274	5
75	Manifestations and Treatment of Acute Graft-Versus-Host Disease1287-1303	10
74	Chronic Graft-versus-Host Disease: Clinical Manifestations and Therapy1304-1324	8
73	Fungal Infections after Hematopoietic Cell Transplantation1346-1366	5
72	Cytomegalovirus Infection1367-1381	5
71	Herpes Simplex Virus Infections1382-1387	6
70	Varicella-zoster Virus Infections1388-1409	5
69	Gastrointestinal and Hepatic Complications1434-1455	4

- 68 Lung Injury Following Hematopoietic Cell Transplantation1456-1472 12
- 67 Kidney and Bladder Complications of Hematopoietic Cell Transplantation1473-1486 2
- 66 Methods for Gene Transfer: Genetic Manipulation of Hematopoietic Stem Cells107-117
- 65 AIDS and Hematopoietic Transplantation: HIV Infection, AIDS, Lymphoma and Gene Therapy1369-1384
- 64 Marrow Transplantation in Thalassemia1407-1416
- 63 Pharmacologic Basis for High-Dose Chemotherapy130-157
- 62 Radiotherapeutic Principles of Hematopoietic Cell Transplantation178-197
- 61 Molecular Inhibition of Gene Expression in Hematopoietic Cells258-271
- 60 The Detection and Significance of Minimal Residual Disease272-285
- 59 Pathology of Hematopoietic Cell Transplantation286-299
- 58 Adoptive Immunotherapy With Antigen-Specific T Cells380-404
- 57 The Evaluation and Counseling of Candidates for Hematopoietic Cell Transplantation447-462
- 56 Clinical and Administrative Support for Hematopoietic Cell Transplant Programs463-468
- 55 Nursing Issues in Hematopoietic Cell Transplantation469-482
- 54 Psychosocial Issues in Hematopoietic Cell Transplantation497-506
- 53 Histocompatibility31-42
- 52 Hematopoietic Cell Procurement, Processing and Transplantation: Regulation and Accreditation529-537
- 51 In Utero Transplantation565-575

- 50 Mobilization of Autologous Peripheral Blood Hematopoietic Cells for Support of High-Dose Cancer Therapy 576-587
- 49 Recombinant Growth Factors After Hematopoietic Cell Transplantation 613-623
- 48 The Hematopoietic Microenvironment 53-61
- 47 Nutritional Support of Hematopoietic Cell Recipients 883-893
- 46 Oral Complications 911-928 1
- 45 Allogeneic Hematopoietic Cell Transplantation for Aplastic Anemia 979-1001
- 44 Allogeneic Hematopoietic Cell Transplantation for Adult Patients With Acute Myeloid Leukemia 1025-1039
- 43 Allogeneic Transplantation for Acute Myeloid Leukemia in Children 1040-1054
- 42 Allogeneic Transplantation for Acute Lymphoblastic Leukemia in Children 1067-1083
- 41 Allogeneic Hematopoietic Cell Transplantation for Multiple Myeloma 1096-1104
- 40 Allogeneic Transplantation for Lymphoma and Chronic Lymphocytic Leukemia 1105-1115
- 39 Hematopoietic Cell Transplantation from HLA Partially Matched Related Donors 1116-1131
- 38 Allogeneic Hematopoietic Cell Transplantation for Solid Tumors 1177-1187
- 37 Autologous and Allogeneic Hematopoietic Cell Transplantation for Hodgkin's Disease 1189-1206
- 36 Autologous Hematopoietic Cell Transplantation for Acute Myeloid Leukemia 1221-1237
- 35 Expansion of Hematopoietic Stem Cells 96-106
- 34 Autologous Hematopoietic Cell Transplantation for Chronic Myeloid Leukemia 1250-1261
- 33 Autologous Hematopoietic Cell Transplantation for AL Amyloidosis 1283-1297

- 32 Hematopoietic Cell Transplantation in Germ Cell Tumors1308-1319
- 31 Hematopoietic Cell Transplantation for Brain Tumors1345-1353
- 30 Hematopoietic Cell Transplantation for Pediatric Patients With Solid Tumors1354-1368
- 29 Genetic Manipulation of Hematopoietic Stem Cells116-128
- 28 Critical Care of the Hematopoietic Cell Transplant Recipient1539-1550
- 27 Secondary Malignancies after Hematopoietic Cell Transplantation1638-1652
- 26 Natural Killer Cells and Allogeneic Hematopoietic Cell Transplantation163-175
- 25 Radioimmunotherapy and Hematopoietic Cell Transplantation351-364
- 24 The Detection and Significance of Minimal Residual Disease376-389
- 23 Biostatistical Methods in Hematopoietic Cell Transplantation406-427
- 22 Hematopoietic Cell Procurement, Processing, and Transplantation: Standards, Accreditation, and Regulation533-543
- 21 Generation of Definitive Engraftable Hematopoietic Stem Cells from Human Embryonic Stem Cells23-35
- 20 Use of Recombinant Growth Factors after Hematopoietic Cell Transplantation645-656
- 19 Hematopoietic Cell Transplantation for Aplastic Anemia705-726
- 18 Hematopoietic Cell Transplantation for Juvenile Myelomonocytic Leukemia751-760
- 17 Hematopoietic Cell Transplantation for Childhood Acute Myeloid Leukemia775-790
- 16 Hematopoietic Cell Transplantation for Hodgkin's Disease860-877
- 15 Non-Hodgkin's Lymphoma878-896

- 14 Autologous Hematopoietic Cell Transplantation for Systemic Light Chain (AL-) Amyloidosis914-930
- 13 Hematopoietic Cell Transplantation for Breast Cancer931-947
- 12 Hematopoietic Cell Transplantation in Germ Cell Tumors948-957
- 11 Hematopoietic Cell Transplantation for Renal Cell and other Solid Tumors958-959
- 10 Hematopoietic Cell Transplantation for Neuroblastoma970-984
- 9 Hematopoietic Cell Transplantation for Other Pediatric Solid Tumors985-1000
- 8 Hematopoietic Cell Transplantation for Patients with Human Immunodeficiency Virus Infection1001-1013
- 7 Hematopoietic Cell Transplantation for Rare Hematologic Malignancies1030-1042
- 6 Management of Relapse after Hematopoietic Cell Transplantation1059-1075
- 5 Hematopoietic Cell Transplantation for Thalassemia1077-1089
- 4 Hematopoietic Cell Transplantation for Fanconi's Anemia1178-1199
- 3 Mechanisms and Treatment of Graft Failure1201-1218
- 2 EpsteinBarr Virus Infection1410-1418
- 1 Common Potential Drug Interactions Following Hematopoietic Cell Transplantation1523-1538